To see the other types of publications on this topic, follow the link: Gómez-Peña.
Journal articles on the topic 'Gómez-Peña'
Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles
Consult the top 50 journal articles for your research on the topic 'Gómez-Peña.'
Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.
You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.
Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.
1
Kraniauskas, John. "Border dialogue: Talking to Guillermo Gómez Peña." Travesia 3, no. 1-2 (1994): 152–78. http://dx.doi.org/10.1080/13569329409361829.
Full text
2
Foster, David William. "Guerreando lenguajes: el teatro de Guillermo Gómez-Peña." Urdimento 1, no. 1 (2018): 85–94. http://dx.doi.org/10.5965/1414573101011997085.
Full text
3
Gómez-Peña, Guillermo, and Lisa Wolford. "Navigating the Minefields of Utopia: A Conversation." TDR/The Drama Review 46, no. 2 (2002): 66–96. http://dx.doi.org/10.1162/105420402320980514.
Full text
4
Gómez-Peña, Guillermo. "Letters from the Road: A Selection of Performance Chronicles." TDR/The Drama Review 46, no. 2 (2002): 97–109. http://dx.doi.org/10.1162/105420402320980523.
Full text
5
Quintana, Alvina E. "Performing Tricksters: Karen Tei Yamashita and Guillermo Gómez-Peña." Amerasia Journal 28, no. 2 (2002): 217–25. http://dx.doi.org/10.17953/amer.28.2.25544l876311v656.
Full text
6
Gómez-Peña, Guillermo. "The New Global Culture, Somewhere between Corporate Multiculturalism and the Mainstream Bizarre (a border perspective)." TDR/The Drama Review 45, no. 1 (2001): 7–30. http://dx.doi.org/10.1162/105420401300079013.
Full textAbstract:
This writing—part essay, part chronicle, and part performance text—deals with the new “global” culture and what Gómez-Peña perceives to be its main risks and contradictions, artistic and pop cultural products, major philosophical trends, and political dilemmas.
7
Catelli, Laura. "Mestizaje, hibridez y transmedialidad. Categorías en tensión en performances y prácticas fronterizas de Guillermo Gómez Peña y La Pocha Nostra." El Taco en la Brea, no. 6 (December 19, 2017): 174–90. http://dx.doi.org/10.14409/tb.v0i6.6970.
Full textAbstract:
El artículo aborda tres categorías, mestizaje, hibridez y transmedialidad, a partir de las prácticas fronterizas de Guillermo Gómez Peña y el grupo de performance La Pocha Nostra. Se propone acercar la categoría de transmedialidad a una serie de preguntas sobre los imaginarios raciales y culturales latinoamericanos que he articulado en otros escritos, especialmente en relación a las categorías de mestizaje e hibridez. Así como mestizaje e hibridez han sido usadas para construir identidades culturales «estables» y han sido teorizadas para deconstruir esas mismas identidades (Bhabha, Pérez Torres), la transmedialidad pareciera reproducir un movimiento si no idéntico, similar en algunos aspectos, algo que la obra de Gómez Peña sugiere por medio de una yuxtaposición constante de las tres categorías. La exacerbación de la transmedialidad en la obra en yuxtaposición permanente con el mestizaje y la hibridez abre preguntas sobre los alcances y efectos políticos de los dispositivos transmediales, poniendo sobre el tapete preguntas de orden político sobre el control de los cuerpos, los movimientos migratorios, el imperialismo, el colonialismo, la globalización.
8
Bragança, Maurício. "Literatura Comparada e Estudos de Performance: tendências, diálogos e desafios no limiar da transdiciplinaridade." Aletria: Revista de Estudos de Literatura 20, no. 1 (2010): 63–75. http://dx.doi.org/10.17851/2317-2096.20.1.63-75.
Full textAbstract:
Resumo: O artigo pretende problematizar o diálogo entre literatura e estudos de performance no que tange ao questionamento do próprio conceito de literatura a partir da emergência de novas teorias da cultura após a década de 1960. De feição transdisciplinar, os estudos de performance convocam, na sua interface com o texto literário, um novo tipo de leitor a partir de um movimento que transforma o texto em ato. Como estudo de caso, convocamos um texto-manifesto de Guillermo Gómez-Peña que performatiza seu discurso através da transgressão às convenções literárias, sem deixar de dialogar com uma tradição de construção deste tipo de narrativa.Palavras-Chave: Literatura comparada; estudos de performance; transdisciplinaridade.Abstract: This article aims to present a dialogue between literature and performance studies based on the new concepts of literature from the emergence of new theories of culture after the 1960s. Marked by transdisciplinarity, the performance studies need a new type of reader at its interface with the literary text, from a movement that transforms the text into action. As a case study, we call a manifest text by Guillermo Gómez-Peña who performs his speech by transgression of literary conventions, while dialogues with a tradition of this kind of narrative.Keywords: Comparative literature; performance studies; transdisciplinarity.
9
Taylor, Diana. "A Savage Performance: Guillermo Gómez-Peña and Coco Fusco's “Couple in the Cage”." TDR/The Drama Review 42, no. 2 (1998): 160–80. http://dx.doi.org/10.1162/dram.1998.42.2.160.
Full text
10
Lozano, Wilfredo. "Sistema de partidos y cambio democrático: aproximaciones al caso dominicano." América Latina Hoy 56 (March 14, 2011): 15–36. http://dx.doi.org/10.14201/alh.7784.
Full textAbstract:
Se analizan las transformaciones de los partidos políticos y del sistema de partidos, tras la desaparición de los líderes fundadores de los tres principales partidos políticos modernos: Bosch (PLD), Peña Gómez (PRD) y Balaguer (PRSC). Se analizan los procesos constitutivos del sistema de partidos y los estilos de liderazgo. Se discute la relación del sistema de partidos con el Estado, destacando su ascendiente neopatrimonialista y la función del clientelismo. Finalmente, se proponen algunas notas destacando el proceso de formación de una élite neopatrimonialista y el manejo clientelar de la política electoral.
11
Foster, Thomas. "Cyber-Aztecs and Cholo-Punks: Guillermo Gómez-Peña's Five-Worlds Theory." Publications of the Modern Language Association of America 117, no. 1 (2002): 43–67. http://dx.doi.org/10.1632/003081202x63500.
Full textAbstract:
In the study of postmodern technocultures, including computer-mediated communication and popular narratives about cyberspace, the status of embodiment has emerged as a key question, especially in the context of popular rhetorics that imagine the Internet as a site of freedom from embodied particularity. But while analyses of gender bending and sexual performance on the Internet abound, the future of race in cyberspace has been relatively neglected. This essay traces recent developments in the work of the Mexican American performance artist Guillermo Gómez-Peña, whose earlier interests in immigration, transnationalism, and border-crossing art have increasingly led him to reflect on the promises and dangers cyberspace poses for racially minoritized groups, to the extent that people who use or study the Internet fantasize cyberspace as a site of subjective border crossing and identity play. The essay looks at the theme of virtual reality in specific performances and at Gómez-Peña's incorporation of new technologies into his work.
12
Pellegrini, Ann. "Habeas Corpus: Behold the Body." TDR/The Drama Review 52, no. 1 (2008): 179–82. http://dx.doi.org/10.1162/dram.2008.52.1.179.
Full textAbstract:
This issue's Critical Acts focuses on “war and other bad shit” in terms of censorship, immigration, and art as a form of political protest and recovery. In “Habeas Corpus,” Ann Pellegrini uses Sally Field's censored Emmy-acceptance speech to exemplify the Bush administration's privatization of mourning as a means “to bind us to acts of fatal violence against an objectified and dehumanized ‘enemy.’” In her account of Luigi Nono's The Forest Is Young and Full of Life, Judy Lochhead examines the possibility of music as activism, noting how history is recycled from the Vietnam War to today. William Bowling and Rachel Carrico describe how art heals in Lakeviews, part of a post-Katrina project. Guillermo Gómez-Peña rages against “border hysteria,” when the “War on Terror” becomes a “war on difference.”
13
Lochhead, Judy. "On Recent Performances of Luigi Nono's The Forest Is Young and Full of Life." TDR/The Drama Review 52, no. 1 (2008): 182–89. http://dx.doi.org/10.1162/dram.2008.52.1.182.
Full textAbstract:
This issue's Critical Acts focuses on “war and other bad shit” in terms of censorship, immigration, and art as a form of political protest and recovery. In “Habeas Corpus,” Ann Pellegrini uses Sally Field's censored Emmy-acceptance speech to exemplify the Bush administration's privatization of mourning as a means “to bind us to acts of fatal violence against an objectified and dehumanized ‘enemy.’” In her account of Luigi Nono's The Forest Is Young and Full of Life, Judy Lochhead examines the possibility of music as activism, noting how history is recycled from the Vietnam War to today. William Bowling and Rachel Carrico describe how art heals in Lakeviews, part of a post-Katrina project. Guillermo Gómez-Peña rages against “border hysteria,” when the “War on Terror” becomes a “war on difference.”
14
Bowling, William, and Rachel Carrico. "Lakeviews: A Bus Tour As a Vehicle for Regrowth in New Orleans." TDR/The Drama Review 52, no. 1 (2008): 190–96. http://dx.doi.org/10.1162/dram.2008.52.1.190.
Full textAbstract:
This issue's Critical Acts focuses on “war and other bad shit” in terms of censorship, immigration, and art as a form of political protest and recovery. In “Habeas Corpus,” Ann Pellegrini uses Sally Field's censored Emmy-acceptance speech to exemplify the Bush administration's privatization of mourning as a means “to bind us to acts of fatal violence against an objectified and dehumanized ‘enemy.’” In her account of Luigi Nono's The Forest Is Young and Full of Life, Judy Lochhead examines the possibility of music as activism, noting how history is recycled from the Vietnam War to today. William Bowling and Rachel Carrico describe how art heals in Lakeviews, part of a post-Katrina project. Guillermo Gómez-Peña rages against “border hysteria,” when the “War on Terror” becomes a “war on difference.”
15
Gómez-Peña, Guillermo. "Border Hysteria and the War against Difference." TDR/The Drama Review 52, no. 1 (2008): 196–203. http://dx.doi.org/10.1162/dram.2008.52.1.196.
Full textAbstract:
This issue's Critical Acts focuses on “war and other bad shit” in terms of censorship, immigration, and art as a form of political protest and recovery. In “Habeas Corpus,” Ann Pellegrini uses Sally Field's censored Emmy-acceptance speech to exemplify the Bush administration's privatization of mourning as a means “to bind us to acts of fatal violence against an objectified and dehumanized ‘enemy.’” In her account of Luigi Nono's The Forest Is Young and Full of Life, Judy Lochhead examines the possibility of music as activism, noting how history is recycled from the Vietnam War to today. William Bowling and Rachel Carrico describe how art heals in Lakeviews, part of a post-Katrina project. Guillermo Gómez-Peña rages against “border hysteria,” when the “War on Terror” becomes a “war on difference.”
16
Gómez-Peña, Guillermo. "Gómez-Peña on Illness, the Human Body, Performance, and Quantum Physics: a psychomagic script for a hard recovery." TDR/The Drama Review 58, no. 2 (2014): 149–62. http://dx.doi.org/10.1162/dram_a_00352.
Full text
17
Mahootian, Shahrzad, and Dana Cole. "Cultural and Transcultural Transgression at the Border: “Art is about Misunderstandings that Happen at the Borderzone”, Guillermo Gómez-Peña." International Journal of the Arts in Society: Annual Review 4, no. 3 (2009): 181–92. http://dx.doi.org/10.18848/1833-1866/cgp/v04i03/35661.
Full text
18
Di Paola, Modesta. "Crossing borders y nuevas creatividades. El pensamiento de frontera en la producción artística de Teresa Margolles y Guillermo Gómez- Peña." Anales de Historia del Arte 30 (November 26, 2020): 109–29. http://dx.doi.org/10.5209/anha.72176.
Full textAbstract:
En el nuevo escenario de la producción teórica y crítica del arte contemporáneo, redefinido por los flujos globales y la movilidad de géneros, disciplinas, comportamientos y metodologías, surge la necesidad de crear nuevas herramientas de interpretación de las prácticas artísticas. Teóricos de varios ámbitos disciplinares como Edward Said, Homi Bhabha, Édouard Glissant, Fernando Ortiz, Walter Mignolo, Gloria Anzaldúa, entre otros, han creado una narrativa de resistencia para deconstruir las estrategias modernistas de igualdad que las ciencias sociales tradicionales han imaginado como sólidas e inamovibles (la nación, la clase, la adscripción político-ideológica). Las teorías del arte sumergidas en el posestructuralismo —con frecuentes incursiones hacia el posmodernismo y el poscolonialismo— son deudoras de estas posiciones conceptuales y revelan el interés hacia la resistencia en contra del proyecto etnocéntrico y universalista de la modernidad. Los artistas mexicanos Teresa Margolles y Guillermo Gómez-Peña, generando una movilidad identitaria y cultural en este escenario posnacional, poshistórico y poscolonial, significan casos de estudio significativos para entender el cambio de paradigma que domina buena parte de la producción artística actual, sobre todo en contextos fronterizos.
19
Martínez-Sáez, Celia. "The Forgotten Flesh: Confronting Western Epistemologies through Parody in Guillermo Gómez-Peña and Coco Fusco's The Couple in the Cage (1992)." Journal of the Midwest Modern Language Association 51, no. 2 (2018): 13–25. http://dx.doi.org/10.1353/mml.2018.0013.
Full text
20
Diabetes & Metabolismo, Asociación Colombiana de Endocrinología. "Diabetes, Obesidad y Lípidos." Revista Colombiana de Endocrinología, Diabetes & Metabolismo 4, no. 2 (2017): 60–76. http://dx.doi.org/10.53853/encr.4.2.119.
Full textAbstract:
Listado
 
 Apolipoprotein E and apolipoprotein C-III-defined HDL Subspecies differ in their lecithin-cholesterol acyl transferase and cholesterol-ester transfer protein content and activity. Amaya-Montoya M, Pinzón-Cortés JA, Silva-Bermúdez LS, Ruiz-Manco D, Pérez-Matos MC, Mendivil CO
 
 Efecto del uso de metformina sobre el perfil tiroideo en pacientes con síndrome de ovarios poliquísticos. Cano RA, Agostini MI, Corzo GA, Cano C, Figueroa L.
 
 
 Características epidemiológicas y clínicas de una cohorte de adultos con cetoacidosis diabética atendidos en un hospital universitario de Colombia. Estudio CAD-EPI. MANIPURA
 
 
 Diagnóstico prenatal de inversión pericéntrica del cromosoma 9 y su asociación con enfermedades metabólicas. Usta C, Torres C, Gómez M, Lynett D, Fernández I, Celis LG.
 
 
 Estrategias para el control del sobrepeso y prevención de la obesidad en la población escolar: una revisión narrativa. Amador E., Montealegre L.
 
 
 Asociación entre variantes en el gen del receptor 1 de adiponectina (ADIPOR1) con diabetes e hipertrigliceridemia en adultos del caribe colombiano. Ruiz Díaz MS, Mora García GJ, Espitia F, Flórez D, Gómez Camargo DE
 
 
 Control glucémico en pacientes hospitalizados en sala general con hiperglucemia en tratamiento con insulinoterapia: situación actual de una clínica de cuarto nivel de atención en el oriente colombiano. Hernández BM, Sánchez ML, Parra GA
 
 
 Estudio de enfermedades crónico-degenerativas, factores de riesgo cardiovascular en escolares. Abordaje desde la medicina traslacional. Celis LG, Russi A, Mendieta Zerón H, Ayala J, Giratá V y Almonacid C.
 
 
 Factores de riesgo para hipertensión arterial en el área rural de Quingeo, Ecuador, 2016. Rina Ortiz, Maritza Torres, Susana Peña, Roberto Añez, Valmore Bermúdez
 
 
 Hemoglobina glucosilada no contribuye al diagnóstico de DM2 y prediabetes en la población colombiana. DIOGENES DE SINOPE
 
 
 II Consenso Latinoamericano de Obesidad. Gómez-Cuevas R., Valenzuela A., Nuila M., Ponce M.L., Deras J., DeLeon C, Aure G., Aguirre H., González J., Marin S., Rojas M.I., Ribera R., Halpern B, Jiménez M.C. Recalde A, Lobato G.
 
 
 Impacto de los edulcorantes sobre los receptores de insulina y la microbiota intestinal, como factores relacionados con la aparición de la diabetes mellitus. Cadena Silvia
 
 
 Indicadores antropométricos como factores de riesgo de hipertensión arterial en estudiantes de la Universidad Metropolitana de Barranquilla. Carmen María Carrero
 
 
 Respuesta aguda del perfil lipídico a dos modalidades de ejercicio físico en mujeres posmenopáusicas. Edmund Halley
 
 
 Liraglutide en el tratamiento de hipoglucemia posprandial como complicación de un bypass gástrico. Reporte de un caso. Guzmán G, Gutiérrez K, Plaza L, Martínez V.
 
 
 Similar cardiometabolic effects of high- versus moderate-intensity training among apparently healthy inactive adults. A randomized clinical trial. Ramírez-Vélez R; Correa-Bautista JE.
 
 
 Manejo de hiperglucemia inducida por esteroides con esquema de insulina NPH en pacientes diabéticos hospitalizados en una unidad de hemato-oncología: resultados de una cohorte prospectiva. Parra GA, Velandia CA, Rodríguez, JD, Ojeda JD, Pérez YT, Osma OO.
 
 
 Prevalencia y factores asociados a la obesidad en el área rural de Cumbe, Ecuador, 2016. Torres M., Ortiz R., Añez R., Delgado F., Bermúdez V., Peña Susana
 
 
 Proyecto PREDICOL: programa de atención en salud comunitaria para la prevención de diabetes tipo 2 y otros factores de riesgo en personas adultas desde atención primaria en los distritos de Barranquilla y Bogotá, 2017-2019. Acosta T., Aschner P., Acosta J., Carvajal L., Navarro E.
 
 
 Proteoma de tejido adiposo subcutáneo en individuos con obesidad, antes y después de cirugía bariátrica. Moreno N.R, Vázquez-Martínez R. y Malagón M.M.
 
 
 Puede ayudar la actividad física al control de la diabetes mellitus: revisión de la evidencia. Lara G.
 
 
 Reducción de la variabilidad glucémica (VG) a las 12 de semanas de tratamiento con insulina Degludec (IDeg) en individuos con diabetes mellitus tipo 1 (DM1) y tipo 2 (DM2) con hipoglucemia medida por monitoreo continuo de glucosa (MCG) retrospectivo. Henao D, Gómez AM, Muñoz O, Rondón M, Colon C, Chica L, Rubio C, León F.
 
 
 Respuesta cardiopulmonar y glucémica en pacientes diabéticos en posquirúrgico cardiovascular luego de un programa de entrenamiento aeróbico interválico. JP
 
 
 Aspectos demográficos de una muestra de pacientes colombianos con diabetes mellitus tipo 1. Diana Clobeth Sarrazola Yepes, Natalia Gómez-Lopera, Jorge García, María Victoria Lopera, Martín Toro, Alejandra Vélez, Juan Manuel Alfaro y Nicolás Pineda-Trujillo
 
 
 Síndrome metabólico en pacientes en posquirúrgico cardiovascular. Pereira JE; Pereira R; Boada L; Peñaranda D.
 
 
 Diferencias en las relaciones entre las masas mineral, magra y grasa del cuerpo entero en 600 hombres y mujeres pre y posmenopáusicas colombianas de hábitos urbanos o rurales. Cure Cure C MD, Ferretti J L, Cure P, López Jaramillo JP, Nocciolino L, Luscher S, Capozza R.
 
 
 Una variante en el gen RNASEH1 interactúa con tagSNPs de HLA en familias colombianas con diabetes mellitus tipo 1. Gómez-Lopera N., Sarrazola Yepes D., Toro M., Lopera M., Alfaro J-M., Pineda-Trujillo N.
 
 
 Variabilidad glucémica asociada a lipohipertrofia en paciente con uso de bomba de infusión de insulina con suspensión automática en hipoglucemia. Reporte de caso. Parra GA, Aristizábal SM
 
21
Residentes, Residentes. "Cardiología." Acta Médica Colombiana 43, no. 2S (2019): 27–54. http://dx.doi.org/10.36104/amc.2018.1393.
Full textAbstract:

 
 C-1. DISMINUCIÓN DE LA MORBIMORTALIDAD EN FALLA CARDIACA, MEJORÍA DE LA FRACCIÓN DE EYECCIÓN Y CLASE FUNCIONAL CON EL USO DE SACUBUTRILO / VALSARTAN (PEÑA QUINTERO HAROLD, KOGA CORREA JENNY CAROLINE, TASCON GUEVARA BRIGITTE NATHALIA 
 C-2. CORAZÓN CARCINOIDE Y TUMOR NEUROENDOCRINO METASTÁSICO (AGUDELO CARLOS, TRUJILLO DANILO, LUNA FREDY, ORTIZ CARLOS, GUERRA JOAQUÍN.)
 C-3. DEXTROCARDIA ADQUIRIDA (AVILA NATALIA, CELEMIN CARLOS, VARGAS JUAN GUILLERMO)
 C-4. ENDOCARDITIS INFECCIOSA EN VÁLVULA PROTÉSICA AORTICA POR STREPTOCOCCUS GORDONII (NAVARRETE LINDA, FUENTES CARLOS, ÁLVAREZ CAMILO, RESTREPO CARLOS, SUPELANO MARIO, MORA JAVIER) 
 C-5. COMPROMISO CARDÍACO EN AMILOIDOSIS (BETANCUR SALAZAR KELLY JOHANNA, RONDÓN CARVAJAL JULIÁN FELIPE, THORRENS RÍOS JOSE GREGORIO)
 C-6. INSUFICIENCIA TRICUSPIDEA PRIMARIA ASOCIADA A INSUFICIENCIA CARDIACA DERECHA, LA VÁLVULA OLVIDADA (MENDOZA FERNÁN, ROMERO JOSÉ, LONDOÑO GABRIEL, IDROVO CAROLINA, MENDOZA LAURA VICTORIA, NÚÑEZ FEDERICO, CAICEDO VÍCTOR)
 C-7. COMUNICACIÓN INTERVENTRICULAR COMO COMPLICACIÓN TEMPRANA POST INFARTO DE CARA ANTERIOR (MENDOZA FERNÁN, LONDOÑO GABRIEL, CASTAÑO ANGIE MARCELA, MENDOZA LAURA VICTORIA, ANDRADE DARÍO,
 FEDERICO NÚÑEZ, CAICEDO VÍCTOR
 C-8. COMPLICACIONES CARDIOVASCULARES DEL CONSUMO DE COCAÍNA (SANTAMARIA ALZA YEISON, HERNANDEZ CELIS ANNIE)
 C-9. PERFIL CLÍNICO Y DEMOGRÁFICO DE PACIENTES CON FALLA CARDIACA AGUDA. ANÁLISIS DESCRIPTIVO DE COHORTE. (JUAN EMILIO, AMAYA NICOLAS, JUAN MARIETTA, ARBELAEZ LINA, CALVO LAUREN, VALENCIA MARGARITA, MARIÑO ALEJANDRO, GARCIA-PEÑA ANGEL)
 C-10. ABSCESO AÓRTICO PERIPROTÉSICO ROTO (CACERES EDWARD, JUAN MARIETTA, OSPINA DIEGO, MOLINA GERMAN, RIOS GIOVANNY, GARCIA-PEÑA ANGEL)
 C-11. MIOCARDITIS Y PUENTE MUSCULAR: ASOCIACIÓN CON MANIFESTACIONES SEMEJANTES AL SINDROME CORONARIO (MENDOZA FERNÁN, MORALES MILENA)
 C-12. INSUFICIENCIA CARDIACA AVANZADA, DIABETES Y CIRROSIS COMO MANIFESTACIONES DE UN CASO DE HEMOCROMATOSIS HEREDITARIA (MENDOZA FERNÁN, ORTIZ PAOLA, MEDINA OSCAR, JARAMILLO CLAUDIA, ARIZA GERARDO)
 C-13. RELACIÓN ENTRE EL RESULTADO DE TROPONINA CARDÍACA Y LA MORTALIDAD EN UN HOSPITAL DE SEGUNDO NIVEL DE ATENCIÓN (ARAUJO DURAN JORGE, CONCHA DIANA, BARROS CAMILO)
 C-14. COMPARACIÓN DE ESCALAS DE PREDICCIÓN DE RIESGO EN DOLOR TORÁCICO, EN UN HOSPITAL DE ALTA COMPLEJIDAD (TORRALBA ADRIÁN FELIPE, NAVARRO ALBERTO, ORTIZ CARLOS)
 C-15. MIOCARDIOPATIA DILATADA PERIPARTO: PRESENTACION DE UN CASO (GRANELA KATYA, BROCHADO LEONARDO)
 C-16. PROTOCOLOS ADAPT VS HEART EN EL DIAGNÓSTICO DEL DOLOR TORÁCICO: DISEÑO DE UN ENSAYO CLÍNICO ALEATORIZADO PRAGMATICO (SPROCKEL JOHN*, DIAZTAGLE JUAN*, CHAVES WALTER, ALVAREZ JOHAN, BOHORQUEZ JUAN, HURTADO EDUARDO, HERRERA GEOBER, ALZATE JUAN, OLAYA ALEJANDRO)
 C-17. AGENESIA DE ARTERIA PULMONAR UNILATERAL EN ADULTO CON TETRALOGÍA DE FALLOT (CASTRO LEIDY, CÁRDENAS LAURA, SPROCKEL JOHN)
 C-18. PERICARDITIS CONSTRICTIVA POR TUBERCULOSIS REPORTE DE CASO CLINICO (GONZÁLEZ YESENIA, ARTETA SHEILA)
 C-19. UTILIDAD DIAGNOSTICA DEL SIGNO DE FRANK EN PACIENTES CON ENFERMDEDAD CARDIOVASCULAR ATENDIDOS EN UN HOSPITAL DE TECER NIVEL (ÁLVAREZ LUIS, BURITICÁ WILSON, CALDERÓN LAURA, LOSADA MARÍA, MACÍAS DANIELA, VERGARA JHON)
 C-20. EXPERIENCIA EN CATETERISMO CARDIACO DERECHO EN PACIENTES CON SOSPECHA DE HIPERTENSION PULMONAR EN EL HOSPITAL GENERAL DE MÉXICO (JURADO YAMILE, CUETO GUILLERMO, GÓMEZ SAMUEL)
 C-21. COMPARACIÓN DE RESULTADOS DE ECOCARDIOGRAMA ESTRÉS Y PRUEBA DE ESFUERZO EN PACIENTES DE CONSULTA ESPECIALIZADA (YASNÓ NAVIA PAOLA ANDREA, LÓPEZ GARZÓN NELSON ADOLFO, MARIA VIRGINIA PINZÓN)
 C-22. ANGIOGRAFÍA CORONARIA: HALLAZGOS Y PERFIL CLÍNICO EN 100 PACIENTES EN LA UNIDAD DE HEMODINAMIA DE UN CENTRO DE REFERENCIA CARDIOVASCULAR, REPORTE PRELIMINAR (DURAN GUTIÉRREZ LUIS FERNANDO, ALVAREZ ROSERO RAFAEL ALBERTO, JIMÉNEZ CANIZALES CARLOS EDUARDO, PEÑA MURCIA ANGIE DANIELA, VARGAS RIVEROS LUIS FERNANDO, SANTOS POLANCO LUIS FERNANDO, MONDRAGÓN CARDONA ÁLVARO EDUARDO)
 C-23. HEMANGIOMA CARDIACO DEL NODO AURICULOVENTRICULAR (HERNÁNDEZ JENIFFER, PINTO DIEGO
 C-24. SÍNDROME DE KOUNIS INDUCIDO POR N-ACETIL CISTEÍNA (PIZZA RESTREPO MARIA JULIANA, ÁLVAREZ MORENO ADRIANA, OCAMPO YEPES MARIA CAMILA, CEBALLOS ZAPATA KATHERINE, THORRENS RIOS JOSE GREGORIO)
 C-25. CARACTERIZACIÓN DE LA POBLACIÓN CON ENDOCARDITIS INFECCIOSA EN EL HOSPITAL DEPARTAMENTAL SANTA SOFÍA DE CALDAS ENTRE EL 2012-2016 (BECERRA LUZ YANETH, GARCÍA CRISTIAN, SÁNCHEZ FABIO MAURICIO)
 C-26. TUMORES CARDIACOS PRIMITIVOS BENIGNOS: MIXOMA CUYA PRESENTACIÓN CLÍNICA FUE UN SÍNDROME CORONARIO AGUDO (MENDOZA FERNÁN, GUTIÉRREZ FELIPE, LONDOÑO GABRIEL, QUINTERO JUAN, ROMERO JOSÉ, VEGA IVÁN, MENDOZA LAURA, NÚÑEZ FEDERICO, ANDRADE DARÍO, CAICEDO VÍCTOR)
 C-27. DERRAME PERICARDICO COMO MANIFESTACIÓN DE MALARIA COMPLICADA (GÓMEZ PACHÓN CAMILO ANDRÉS, CRIOLLO VARÓN KEVIN LEANDRO, FIGUEROA CRISTIAN, TORRES DAVID, DUQUE RUBÉN, PÉREZ FRANCO JAIRO ENRIQUE.)
 C-28. PERICARDITIS POSTINFARTO ASOCIADO A HEMOPERICARDIO Y TAPONAMIENTO CARDIACO (RAMIREZ GARCIA MONICA, CORREA ALDANA JOHN JAIRO, PUENTES CASTRILLON MARIA ELCY, FIERRO RODRIGUEZ DORA EMILIA, DOMINGUEZ RUIZ JUAN DIEGO)
22
Johnson, Colin. "Tensión en la superficie: Improvisando el Performance de la Materialidad Tecnológica en la Obra Glitchbody/Nanostalgia [1454-2015]." Corpo Grafías Estudios críticos de y desde los cuerpos 6, no. 6 (2019): 153–66. http://dx.doi.org/10.14483/25909398.14235.
Full textAbstract:
En la primavera de 2015, UC (Universidad de California) Davis invitó al artista del performance Guillermo Gomez-Peña a colaborar en una pieza llamada Glitchbody / Nanostalgia [1454-2015]. Glitch intentó involucrar tecnologías de vigilancia social como Google Glass con las carnes, movimientos e imaginarios de cuerpos humanos. La performance final fue precedida por una semana de juegos y talleres intensivos, un ensayo realizado en colaboración con muchos de la comunidad de UC Davis. Este documento comienza repitiendo el marco que Glitchbody promulgó: uno que separaba el juego afectivo e improvisatorio del espacio de ensayo de un más representacional y en ocasiones fetichista, despliegue de tecnología en el performance. Al segregar los procesos para desarrollar el trabajo en el ensayo de las tecnologías digitales y conexiones en red que formaron tanto la ocasión para, como la atmosfera del performance, éste enmarcó la tecnología en un modo “prostético”, descuidando el potencial incorporado y las consecuencias materiales de los medios digitales. En este escrito, yo argumento que las nuevas tecnologías mediáticas, además de ser parte del medio (milieu) socio-situado para el performance, deben ser vistas como cuerpos con los cuales contender e improvisar.
 Performance jams’ son las metodologías pedagógicas desarrolladas por Gómez-Peña (2011) en conjunción con el colectivo transdisciplinario de arte “La Pocha Nostra”. El jam es utilizado para germinar nuevas ideas, imágenes y personas para la noche del performance final. En estos espacios de improvisación, cuerpos entrenados de formas distintas se tocan y se mueven entre sí de maneras innovadoras. Al interceptar pensadores como Lipsitz (2013) y Goldman (2007) con trabajos de estudios de los medios sobre prótesis (Sobchack, 2004) glitches (Krapp, 2011), y estudios de la ciencia y la tecnología sobre materialidad (Rubio, 2014), yo argumento que la necesidad política de la improvisación tanto en las artes como en el activismo debe incluir una nebulosa más amplia de contacto y del tocar que incluye cuerpos no humanos y escalas de tecnologías digitales. Involucrar la tensión superficial que existe a los bordes de la piel y la pantalla requiere que atendamos a cómo las prácticas de ensayo excluyen posibilidades a través del enmarcar la tecnología fuera de las técnicas.
23
Trombold, John. "Américo Paredes's Development of a Border Outlaw." Prospects 24 (October 1999): 249–59. http://dx.doi.org/10.1017/s0361233300000363.
Full textAbstract:
In their considerations of Chicanola border poetry and narrative, Gloria Anzaldúa, Guillermo Gómez-Peña, and José David Saldívar have suggested that the cultural condition of the border writer addresses central concerns of contemporary American culture and what one can regard — as I try to do here — as its aspiring cultural outlaws. In the context of their postmodern approaches to culture the notion of the American frontier outlaw has a rather archaic ring, for such an identity recalls 19th–century constructions of self and an underlying belief in individual agency. Even in the 1930s the figure of the folkloric Tejano rebel existed in a similar historical halfway house, one in which the idea of the Mexican outlaw is both utterly anachronistic and politically relevant. Nonetheless, the traditional heroic outlaw of Tejano balladry — corridos — still has the power to signify a legacy of opposition to Anglo power, and the themes of such balladry persist today in the form of legal conflict over unresolved land claims (Verhovek), as if yesterday's outlaw has materialized from legend and taken form as lawful claimant. Thus it is valuable to see how the concerns of contemporary theory can be related to antiquated legends and to note any intermediary texts located in a moment between the late 20th-century present and the mid-19th-century past. Arguably, Américo Paredes's 1930s novel George Washington Gomez prefigures the newly lawful claims of those heir to the mythos of legendary outlaws and at the same time prefigures postmodern border theory. The novel underscores the divided character of a culture inheriting a folkloric tradition in a newly modern American context and elaborates on themes pertinent to a postmodern one.
24
Petrov, Alfredo. "Minerales y Minas de España. Vol. 9: Silicatos [in Spanish] by Miguel Calvo. Order from Christian Peña, Fundación Gómez Pardo, Alenza, 1, 28003 Madrid, Spain; publicaciones@fgomezpardo.es. 767 pages; 2018; €60 plus shipping (hardbound)." Rocks & Minerals 94, no. 5 (2019): 477. http://dx.doi.org/10.1080/00357529.2019.1619142.
Full text
25
Prieto-Peña, D., P. Bernabéu, P. Vela-Casasempere, et al. "AB0366 TOCILIZUMAB FOR TAKAYASU ARTERITIS: MULTICENTER STUDY OF 54 WHITE PATIENTS." Annals of the Rheumatic Diseases 80, Suppl 1 (2021): 1208.2–1209. http://dx.doi.org/10.1136/annrheumdis-2021-eular.1747.
Full textAbstract:
Background:Tocilizumab (TCZ) has shown to be effective for large vessel vasculitis including Takayasu arteritis (TAK) (1-3). Most evidence in TAK comes from Asian patients. However, white patients seem to have different clinical and prognostic features.Objectives:Our aims were to: a) assess the efficacy and safety of TCZ in white patients with refractory TAK, b) determine if clinical improvement correlates with imaging outcomes, c) compare TCZ in monotherapy (TCZMONO) vs combined with conventional immunosuppressive drugs (TCZCOMBO)Methods:Multicenter study of white patients with refractory TAK who received TCZ.Outcomes variables were remission, glucocorticoid-sparing effect, improvement in imaging techniques, and adverse events. A comparative study between patients who received TCZMONO and TCZCOMBO was performed.Results:54 patients (46 women/8 men; median age 42.0 [32.5-50.5] years). TCZ was started after 12.0 [3.0-31.5] months since TAK diagnosis. Remission was achieved in 12/54 (22.2%), 19/49 (38.8%), 23/44 (52.3%) and 27/36 (75%) at 1, 3, 6 and 12 months, respectively. Prednisone dose was reduced from 30.0 [12.5-50.0] to 5.0 [0.0-5.6] mg/day at 12 months (Table 1). 10 (26.3%) of the 38 patients in whom an imaging follow-up test was performed showed no radiographic improvement after a median of 9.0 [6.0-14.0] months. 4 of them were in clinical remission.23 (42.6%) patients were on TCZMONO and 31 (57.4%) on TCZCOMBO: MTX (n=28), cyclosporine A (n=2), azathioprine (n=1). Patients on TCZCOMBO were younger (38.0 [27.0-46.0] vs 45 [38.0-57.0] years; p= 0.048), with a trend to longer TAK duration (21.0 [6.0-38.0] vs 6.0 [1.0-23.0] months; p= 0.08) and higher C-reactive protein (2.4 [0.7-5.6] vs 1.3 [0.3-3.3] mg/dL; p=0.16). Despite these differences, similar outcomes were observed in both groups (log rank p=0.862) (Figure 1). Relevant adverse events were reported in 6 (11.1%) patients, but only 3 developed severe events that required TCZ withdrawal.Table 1.Baselinen=54Month 1N=54Month 3N=49Month 6N=44Month 12N=36Clinical remission, n (%)12 (22.2)19 (38.8)23 (52.3)27 (75.0)Laboratory improvementCRP (mg/dL), median [IQR]1.5 [0.5-3.5]0.2 [0.1-0.7]*0.2 [0.5-0.5]*0.2 [0.1-0.5]*0.1 [0.0-0.4]*ESR (mm/1sthour), median [IQR]30.5 [8.7-52.7]7.0 [3.0-14.0]*4.5 [2.0-8.0]*5.0[2.0-6.0]*4.0 [2.0-9.5]*Hemoglobin (g/dL), mean ± SD12.4 ±1.513.0 ±1.2*13.0 ±1.4*13.2 ±1.5*12.9 ±1.6*Prednisone dose, median [IQR]30.0 [12.5-50.0]20.0 [10.0-30.0]*10.0 [5.0-20.0]*5.0 [5.0-10.5]*5.0 [0.0-5.6]*CRP: C-Reactive Protein; ESR: Erythrocyte Sedimentation Rate; IQR: interquartile range; n: number. *p<0.01 vs baseline (Wilcoxon test).Conclusion:TCZ is effective and safe in white patients with refractory TAK. A discordance between clinical and imaging activity assessment may exist.References:[1]Prieto Peña D et al. Clin Exp Rheumatol 2020 Nov 27. PMID: 33253103.[2]Loricera J, et al. Clin Exp Rheumatol 2016; 34:S44-53. PMID: 27050507.[3]Calderón-Goercke M, et al. Semin Arthritis Rheum 2019; 49:126-35. PMID: 30655091Disclosure of Interests:Diana Prieto-Peña Grant/research support from: DP-P has received research support from UCB Pharma, Roche, Sanofi, Pfizer, AbbVie and Lilly., Pilar Bernabéu: None declared, Paloma Vela-Casasempere: None declared, J. Narváez: None declared, Carlos Fernández-López: None declared, Mercedes Freire González: None declared, Beatriz González-Alvarez: None declared, Roser Solans-Laqué: None declared, Jose Luis Callejas-Rubio: None declared, Norberto Ortego: None declared, Carlos Fernández-Díaz: None declared, Esteban Rubio Romero: None declared, SALVADOR GARCÍA MORILLO: None declared, Mauricio Minguez: None declared, Cristina Fernández-Carballido: None declared, Eugenio de Miguel: None declared, Sheila Melchor: None declared, Eva Salgado-Pérez: None declared, Beatriz Bravo: None declared, Susana Romero-Yuste: None declared, Juan Salvatierra: None declared, Cristina Hidalgo: None declared, Sara Manrique Arija: None declared, C. Romero-Gómez: None declared, Patricia Moya: None declared, Noelia Alvarez-Rivas: None declared, Javier Mendizabal: None declared, Francisco Miguel Ortiz Sanjuan: None declared, I. Pérez de Pedro: None declared, JOSE LUIS ALONSO VALDIVIESO: None declared, Pérez Sánchez Laura: None declared, Roldán Molina Rosa: None declared, Nagore Fernández-Llanio: None declared, Ricardo Gómez de la Torre: None declared, Silvia Suarez: None declared, María Jesús Montesa: None declared, Monica Delgado Sanchez: None declared, J. Loricera: None declared, Belén Atienza-Mateo: None declared, Santos Castañeda: None declared, Miguel A González-Gay Grant/research support from: MAG-G received grants/research supports from Abbvie, MSD, Jansen and Roche and had consultation fees/participation in company sponsored speaker´s bureau from Abbvie, Pfizer, Roche, Sanofi, Lilly, Celgene and MSD, Ricardo Blanco Grant/research support from: RB received grants/research supports from Abbvie, MSD and Roche, and had consultation fees/participation in company sponsored speaker´s bureau from Abbvie, Lilly, Pfizer, Roche, Bristol-Myers, Janssen, UCB Pharma and MSD.
26
Schotzko, T. Nikki Cesare. "Guillermo Gómez-Peña and Laura Levin, ed. Conversations across Borders: a Performance Artist Converses with Theorists, Curators, Activists, and Fellow ArtistsLondon; New York; Calcutta: Seagull Books, 2011. 360 p. £28.00. ISBN: 978-1-90649-750-7." New Theatre Quarterly 30, no. 2 (2014): 199–200. http://dx.doi.org/10.1017/s0266464x14000347.
Full text
27
Y Memoria, Pasado. "Reseñas de libros." Pasado y Memoria. Revista de Historia Contemporánea, no. 18 (June 28, 2019): 441. http://dx.doi.org/10.14198/pasado2019.18.18.
Full textAbstract:
Contiene: SÁNCHEZ, Raquel y SAN NARCISO, David (coord.), La cuestión de palacio. Corte y cortesanos en la España Contemporánea, Granada, Comares, 2018, 327 pp. / ESTHER COLLADO FERNÁNDEZ; HIGUERAS CASTAÑEDA, Eduardo, Pablo Correa y Zafrilla (1842-1888). Republicanismo y cuestión social en la España del Ochocientos, Toledo, Almud Ediciones, 2018, 239 pp. / ADAM ABBOU FRANCÉS; MENDIOLA, Ignacio y OVIEDO SILVA, Daniel (coords.), Relatos infames. Breve historia de crimen y castigo, Barcelona, Anthropos, 2017, 388 pp. / FERNANDO JIMÉNEZ HERRERA; GARCÍA DE CORTÁZAR, Fernando, España, entre la rabia y la idea, Madrid, Alianza Editorial, 2018, 445 pp. / ANTONIO MOLINER PRADA; DÍAZ MARÍN, Pedro, Política de Estado. Los discursos de la Corona durante la Década Moderada, Alacant, Publicaciones de la Universitat d’Alacant, 2018. / ESTHER COLLADO FERNÁNDEZ; ZABALGOITIA HERRERA, Mauricio (ed.), Hombres en peligro. Género, nación e imperio en la España de cambio de siglo (XIX-XX), Madrid y Fráncfort, Iberoamericana-Vervuert, 2017, 298 pp. / ELIA BLANCO RODRÍGUEZ; GALLEGO FRANCO, Henar (ed.), Feminidades y masculinidades en la historiografía de género, Granada, Editorial Comares, 2018, 246 pp. / CARLOS MARTOS FERRER; GINARD, David, Aurora Picornell. Feminismo, comunismo y memoria republicana en el siglo XX, Granada, Comares Historia, 2018, 128 pp. / NATALIA GARIS PUERTO; FERNÁNDEZ PRIETO, Lourenzo y HERVELLA GARCÍA, Gustavo (eds.): GARCÍA DEL REAL, Carlota y GARCÍA DEL REAL Fernanda, Historia de la guerra civil contada por dos hermanas. Memorias de golpe, revolución y guerra, edición a cargo de Lourenzo Fernández Prieto y Gustavo Hervella García, Granada, Comares, 2018, 141 pp. / GLICERIO SÁNCHEZ RECIO; EGIDO, Ángeles y MONTES, Jorge J. (eds.), Mujer, franquismo y represión. Una deuda histórica, Madrid, Sanz y Torres, 2018, 441 pp. / MÉLANIE IBÁÑEZ DOMINGO; ROIG PRUÑONOSA, Neus, No llores que vas a ser feliz. El tráfico de bebés en España: de la represión al negocio (1938-1996), Barcelona, Ático de los Libros, 2018, 428 pp. / CARLOS ÁLVAREZ FERNÁNDEZ; ORTIZ HERAS, Manuel (coord.), ¿Qué sabemos del franquismo? Estudios para comprender la dictadura de Franco, Granada, Comares, 2018, 287 pp. / GLICERIO SÁNCHEZ RECIO; VADILLO MUÑOZ, Julián, Del pensamiento a la organización. Socialismo en el siglo XIX. Raíces, origen y desarrollo del laboratorio socialista antiestatal en el siglo XIX, Madrid, Queimada Ediciones, 2018, 162 pp. / SAMUEL CALATAYUD SEMPERE; MORENO FONSERET, Roque y PAYÁ LÓPEZ, Pedro (eds.), Memoria y justicia transicional en Europa y América Latina, Granada, Comares, 2018, 237 pp. / MARÍA LUISA RICO GÓMEZ; BARTOLUCCI, Mónica Inés, La juventud maravillosa: la peronización y los orígenes de la violencia política 1958-1972, Sáenz Peña, UNTREF, 2017, 276 pp. / CRISTIAN ANDRÉS DI RENZO.
28
Pulito-Cueto, V., S. Remuzgo Martinez, F. Genre, et al. "AB0094 INCREASE OF ENDOTHELIAL PROGENITOR CELLS IN SYSTEMIC SCLEROSIS-ASSOCIATED INTERSTITIAL LUNG DISEASE." Annals of the Rheumatic Diseases 80, Suppl 1 (2021): 1076.1–1076. http://dx.doi.org/10.1136/annrheumdis-2021-eular.2350.
Full textAbstract:
Background:Endothelial progenitor cells (EPC), involved in vasculogenesis and endothelial tissue repair, have been described as relevant players in vascular and connective tissue diseases [1-2]. In this regard, a previous study of our group disclosed that the degree of EPC frequency may help to identify the presence of interstitial lung disease (ILD) in rheumatoid arthritis patients [3]. Given that ILD is the main cause of mortality in patients with systemic sclerosis (SSc) [1, 4-6], the understanding of the role of EPC in the mechanism of SSc-ILD+ vasculopathy is crucial.Objectives:To assess the potential role of EPC on vascular dysfunction associated with the presence of ILD in patients with SSc.Methods:Peripheral venous blood was collected from a total of 39 patients with SSc, 20 with ILD (SSc-ILD+) and 19 without ILD (SSc-ILD-). All subjects were recruited from the Rheumatology and Pneumology departments of Hospital Universitario Marqués de Valdecilla, Santander, Spain. Quantification of EPC was analyzed by flow cytometry. EPC were considered as CD34+, CD45Low, CD309+ and CD133+.Results:Statistically significant differences in EPC frequency between patients with SSc-ILD+ and patients with SSc-ILD- were disclosed. Specifically, an increase of EPC frequency was observed in SSc-ILD+ patients when compared to patients with SSc-ILD- (mean ± standard deviation: 0.033 ± 0.012 versus 0.021 ± 0.017, respectively, p=0.012).Conclusion:Our results suggest a potential role of EPC on vascular damage associated with the manifestation of ILD in patients with SSc.References:[1]Eur J Rheumatol 2020;7(Suppl 3):S139-S146.[2]Arthritis Rheum 2009;60(11):3168-79.[3]J Clin Med 2020;9(12):4098.[4]Ann Rheum Dis 2007;66(7):940-4.[5]Rheumatology (Oxford) 2010;49(12):2375-80.[6]Eur Respir Rev 2015;24(135):102-14.Acknowledgements:Personal funds, VP-C: PREVAL18/01 (IDIVAL); SR-M: RD16/0012/0009 (ISCIII-ERDF); LL-G: INNVAL20/06 (IDIVAL); RP-F: START PROJECT (FOREUM); RL-M: Miguel Servet type I CP16/00033 (ISCIII-ESF).Disclosure of Interests:Verónica Pulito-Cueto: None declared, Sara Remuzgo Martinez: None declared, Fernanda Genre: None declared, Belén Atienza-Mateo: None declared, Victor Manuel Mora-Cuesta: None declared, David Iturbe-Fernández: None declared, Leticia Lera-Gómez: None declared, Raquel Pérez-Fernández: None declared, Diana Prieto-Peña: None declared, Virginia Portilla: None declared, Ricardo Blanco Speakers bureau: Abbvie, Pfizer, Roche, Bristol-Myers, Janssen and MSD, Consultant of: Abbvie, Pfizer, Roche, Bristol-Myers, Janssen and MSD, Grant/research support from: Abbvie, MSD and Roche, Alfonso Corrales: None declared, Jose Manuel Cifrián-Martínez: None declared, Raquel López-Mejías: None declared, Miguel A González-Gay Speakers bureau: Pfizer, Abbvie, MSD, Grant/research support from: Pfizer, Abbvie, MSD
29
Residentes, Residentes. "Trabajos de investigación residentes." Acta Médica Colombiana 43, no. 2S (2019): 15–26. http://dx.doi.org/10.36104/amc.2018.1392.
Full textAbstract:

 TIR-1. ANEMIA ADQUIRIDA EN EL HOSPITAL Y FACTORES ASOCIADOS: UNA COHORTE RETROSPECTIVA DE PACIENTES MEDICOS HOSPITALIZADOS (MATEUS JUAN, ALZA JHONGERT, CÁRDENAS JORGE, CASTAÑEDA, ANDRÉS, WANCJER BENJAMÍN)
 TIR-2. USO DE LA ESCALA DE CHARLSON COMO PREDICTOR INDEPENDIENTE DE ESTANCIA HOSPITALARIA PROLONGADA EN PACIENTES ADULTOS AL MOMENTO DE INGRESO A URGENCIAS (GARCÍA ÁNGEL ALBERTO, RODRÍGUEZ MARÍA ANGÉLICA, SOTELO JORGE ENRIQUE, MAYORGA VIVIANA, SERRANO PAULA, JURADO NATALLIE, PARIS GABRIELA, JIMÉNEZ CAMILO, GARZÓN ANDRÉS, CANO CARLOS ALBERTO, MORENO ATILIO, AGUIAR LEONAR)
 TIR-3. EFICACIA DE LA TRIPLE TERAPIA EN PACIENTES DIABÉTICOS TIPO 2 NO CONTROLADOS: ESTUDIO EN VIDA REAL (BEDOYA VANESSA, OSORIO LUIS M., MUÑOZ JENNY, SALGADO CARLOS, CASANOVA MARÍA E., CARVAJAL REYNALDO Y ABREU ALÍN)
 TIR-4. FACTORES DE RIESGO ASOCIADOS A ESTANCIA HOSPITALARIA PROLONGADA EN PACIENTES CON FALLA CARDÍACA AGUDA (ARBELAEZ-COLLAZOS LINA, CALVO-BETANCOURT LAUREN, VALENCIA-MEJIA MARGARITA, JUAN MARIETTA, AMAYA NICOLAS, JUAN EMILIO, MARIÑO ALEJANDRO, GARCIA-PEÑA ANGEL. )
 TIR-5. ALTERACIONES HEMATOLÓGICAS EN PACIENTES COLOMBIANOS CON LUPUS ERITEMATOSO SISTÉMICO (SANTAMARÍA-ALZA YEISON, COY QUIROGA AMALIA, ALARCÓN GÓMEZ ZULLY MARCELA, SÁNCHEZ-BAUTISTA JULIÁN DAVID, FAJARDORIVERO JAVIER ENRIQUE, FIGUEROA PINEDA)
 TIR-6. FACTORES PREDICTORES DE MORTALIDAD EN PACIENTES CON ENFERMEDAD CORONARIA Y COMPROMISO DEL TRONCO PRINCIPAL IZQUIERDO (MIRANDA-ARBOLEDA ANDRÉS F., CARDONA DANIEL, GARCÍA KAREN, URIBE CARLOS E., FERNÁNDEZ-CADAVID ANDRÉS, RODRÍGUEZ ARTURO E., SENIOR JUAN M)
 TIR-7. CONCORDANCIA ENTRE ESCALAS FRAMINGHAM ATP III, SCORE Y ACC/AHA 2013, EN UNA COHORTE DE PACIENTES EN UN HOSPITAL DE CUARTO NIVEL EN EL AÑO 2015 (MANCERA RINCÓN PEDRO, GIRAL GIRALDO HELMAN EDUARDO, RIZO TELLO VÍCTOR ZEIN, BARRERA GARAVITO EDGAR CAMILO
 TIR-8. RENDIMIENTO DIAGNÓSTICO DE TRES REGLAS DE PREDICCIÓN CLÍNICA PARA EMBOLIA PULMONAR (ORTIZ SANTIAGO, FAIZAL IVETTE, AGUIRRE GUILY, CEPEDA ANDRÉS, MARTINEZ LAURA, RAMÍREZ DAVID) 
 TIR-9. COMPORTAMIENTO DEL SINDROME DE CUSHING EN UN CENTRO DE SALUD NIVEL IV DE LA CIUDAD DE CALI (SALGADO CIFUENTES CARLOS ALBERTO, MUÑOZ LOMBO JENNY PATRICIA, BEDOYA JOAQUI VANESSA, OSORIO CORREA CINDY VERÓNICA, TABARES BURBANO ADRIÁN ANDRES, ABREU LOMBA ALIN)
 TIR-10. ESCALA DE STOP-BANG COMO TAMIZAJE PARA IDENTIFICAR SUJETOS CON RIESGO DE SÍNDROME DE APNEA HIPOPNEA DEL SUEÑO, EN PACIENTES CON CEFALEA PRIMARIA CRÓNICA QUE ASISTEN A LA CONSULTA EXTERNA DE NEUROLOGÍA EN EL HOSPITAL MILITAR CENTRAL (HENRÍQUEZ ORTIZ SAYURIS, HINCAPIÉ DÍAZ GUSTAVO, GUZMÁN MOLANO LUISA, BASTIDAS GOYES ALIRIO, MANTILLA BARBARITA)
 TIR-11. IMPACTO DE LOS ANALOGOS DE SOMATOSTATINA EN EL MANEJO DE ACROMEGALIA (OSORIO CORREA CINDY VERÓNICA, SALGADO CARLOS ALBERTO, CARVAJAL REYNALDO, ABREU LOMBA ALIN)
 TIR-12. FACTORES ASOCIADOS A INJURIA RENAL AGUDA EN PACIENTES CON TRASPLANTE HEPÁTICO EN UN HOSPITAL DE CUARTO NIVEL (JUAN CASTELLANOS-DE LA HOZ, JULIÁN NARANJO MILLÁN, EDGAR BARRERA GARAVITO)
 
30
Remuzgo Martinez, S., F. Genre, V. Pulito-Cueto, et al. "AB0012 ROLE OF IRF5 GENE ON THE PATHOGENESIS OF IMMUNOGLOBULIN-A VASCULITIS." Annals of the Rheumatic Diseases 79, Suppl 1 (2020): 1309.1–1310. http://dx.doi.org/10.1136/annrheumdis-2020-eular.1023.
Full textAbstract:
Background:Interferon signaling pathway plays a relevant role in autoimmunity. Genetic variants in theinterferon regulatory factor (IRF) 5gene, that encodes the major regulator of the type I interferon induction [1], have been related to the development of several inflammatory diseases [2].Objectives:To determine the influence ofIRF5on Immunoglobulin-A vasculitis (IgAV), an inflammatory vascular disease.Methods:ThreeIRF5polymorphisms (rs2004640, rs2070197 and rs10954213) representative of 3 different haplotype blocks were genotyped in 372 Caucasian patients with IgAV and 876 sex and ethnically matched healthy controls.Results:No statistically significant differences between patients with IgAV and controls were observed when eachIRF5polymorphism was analyzed independently. Similarly, no statistically significant differences between patients with IgAV and controls were found whenIRF5polymorphisms were evaluated combined conforming haplotypes. Additionally, there were no statistically significant differences in genotype, allele and haplotype frequencies ofIRF5when patients with IgAV were stratified according to the age at disease onset or to the presence/absence of gastrointestinal or renal manifestations.Conclusion:Our results do not support an influence ofIRF5on the pathogenesis of IgAV.References:[1]Nat Immunol 2011; 12: 231-8;[2]Arthritis Res Ther 2014; 16: R146.Acknowledgments:This study was supported by European Union FEDER funds and “Fondo de Investigaciones Sanitarias” (grant PI18/00042) from ‘Instituto de Salud Carlos III’ (ISCIII, Health Ministry, Spain). RL-M is a recipient of a Miguel Servet type I programme fellowship from the ISCIII, co-funded by the European Social Fund (ESF, `Investing in your future´) (grant CP16/00033). SR-M is supported by funds of the RETICS Program (RD16/0012/0009) (ISCIII, co-funded by the European Regional Development Fund (ERDF)). VP-C is supported by a pre-doctoral grant from IDIVAL (PREVAL 18/01). LL-G is supported by funds of PI18/00042 (ISCIII, co-funded by ERDF).Disclosure of Interests:Sara Remuzgo Martinez: None declared, Fernanda Genre: None declared, Verónica Pulito-Cueto: None declared, D. Prieto-Peña: None declared, Belén Atienza-Mateo: None declared, Belén Sevilla: None declared, Javier Llorca: None declared, Norberto Ortego: None declared, Leticia Lera-Gómez: None declared, Maite Leonardo: None declared, Ana Peñalba: None declared, María Jesús Cabero: None declared, Luis Martín-Penagos: None declared, Jose Alberto Miranda-Filloy: None declared, Antonio Navas Parejo: None declared, Javier Sanchez Perez: None declared, Maximiliano Aragües: None declared, Esteban Rubio: None declared, MANUEL LEON LUQUE: None declared, Juan María Blanco-Madrigal: None declared, E. Galindez: None declared, Javier Martin Ibanez: None declared, Santos Castañeda: None declared, Ricardo Blanco Grant/research support from: Abbvie, MSD and Roche, Consultant of: Abbvie, Pfizer, Roche, Bristol-Myers, Janssen and MSD, Speakers bureau: Abbvie, Pfizer, Roche, Bristol-Myers, Janssen, Lilly and MSD, Miguel A González-Gay Grant/research support from: Pfizer, Abbvie, MSD, Speakers bureau: Pfizer, Abbvie, MSD, Raquel López-Mejías: None declared
31
Genre, F., S. Remuzgo Martinez, V. Pulito-Cueto, et al. "AB0011 INFLUENCE OF IL17A GENE ON THE PATHOGENESIS OF IMMUNOGLOBULIN-A VASCULITIS." Annals of the Rheumatic Diseases 79, Suppl 1 (2020): 1309.2–1309. http://dx.doi.org/10.1136/annrheumdis-2020-eular.641.
Full textAbstract:
Background:Cytokines signaling pathway genes represent a key component of the genetic network implicated in the pathogenesis of Immunoglobulin-A vasculitis (IgAV) [1], an inflammatory vascular pathology.Interleukin (IL)17Ais a genetic risklocusfor autoimmune diseases, such as giant cell arteritis [2] and spondyloarthritis [3].Objectives:To determine the potential influence ofIL17Aon IgAV.Methods:FiveIL17Atag polymorphisms (rs4711998, rs8193036, rs3819024, rs2275913 and rs7747909) were genotyped in 360 Caucasian patients with IgAV and 1,003 sex and ethnically matched healthy controls.Results:No statistically significant differences between patients with IgAV and healthy controls were observed when eachIL17Agenetic variant was analyzed independently. Similarly, no statistically significant differences between patients with IgAV and healthy controls were found when the fiveIL17Apolymorphisms were evaluated combined conforming haplotypes. In addition, there were no statistically significant differences in genotype, allele and haplotype frequencies ofIL17Awhen patients with IgAV were stratified according to the age at disease onset or to the presence/absence of gastrointestinal or renal manifestations.Conclusion:Our results do not support an influence ofIL17Aon the pathogenesis of IgAV.References:[1]Autoimmun Rev 2018; 17: 301-15[2]Ann Rheum Dis 2014; 73: 1742-5[3]Mediators Inflamm 2018; 2018: 1395823.Acknowledgments:This study was supported by European Union FEDER funds and “Fondo de Investigaciones Sanitarias” (grant PI18/00042) from ‘Instituto de Salud Carlos III’ (ISCIII, Health Ministry, Spain). RL-M is a recipient of a Miguel Servet type I programme fellowship from the ISCIII, co-funded by the European Social Fund (ESF, `Investing in your future´) (grant CP16/00033). SR-M is supported by funds of the RETICS Program (RD16/0012/0009) (ISCIII, co-funded by the European Regional Development Fund (ERDF)). VP-C is supported by a pre-doctoral grant from IDIVAL (PREVAL 18/01). LL-G is supported by funds of PI18/00042 (ISCIII, co-funded by ERDF).Disclosure of Interests:Fernanda Genre: None declared, Sara Remuzgo Martinez: None declared, Verónica Pulito-Cueto: None declared, D. Prieto-Peña: None declared, Belén Atienza-Mateo: None declared, Belén Sevilla: None declared, Javier Llorca: None declared, Norberto Ortego: None declared, Leticia Lera-Gómez: None declared, Maite Leonardo: None declared, Ana Peñalba: None declared, María Jesús Cabero: None declared, Luis Martín-Penagos: None declared, Jose Alberto Miranda-Filloy: None declared, Antonio Navas Parejo: None declared, Diego de Argila: None declared, Maximiliano Aragües: None declared, Esteban Rubio-Romero: None declared, MANUEL LEON LUQUE: None declared, Juan María Blanco-Madrigal: None declared, E. Galindez: None declared, Javier Martin Ibanez: None declared, Santos Castañeda: None declared, Ricardo Blanco Grant/research support from: Abbvie, MSD and Roche, Consultant of: Abbvie, Pfizer, Roche, Bristol-Myers, Janssen and MSD, Speakers bureau: Abbvie, Pfizer, Roche, Bristol-Myers, Janssen, Lilly and MSD, Miguel A González-Gay Grant/research support from: Pfizer, Abbvie, MSD, Speakers bureau: Pfizer, Abbvie, MSD, Raquel López-Mejías: None declared
32
Pulito-Cueto, V., S. Remuzgo Martinez, F. Genre, et al. "AB0026 DECREASE OF ANGIOGENIC T CELLS IN CONNECTIVE TISSUE DISEASE-ASSOCIATED INTERSTITIAL LUNG DISEASE." Annals of the Rheumatic Diseases 80, Suppl 1 (2021): 1046.3–1047. http://dx.doi.org/10.1136/annrheumdis-2021-eular.2676.
Full textAbstract:
Background:Interstitial lung disease (ILD) is one of the most significant complications of connective tissue diseases (CTD), leading to an increase of the morbidity and mortality in patients with CTD [1]. A specific T cell subset termed angiogenic T cells (TAng), that promote endothelial repair and revascularization, have been involved in the pathogenesis of CTD [2-4]. However, to the best of our knowledge, no information regarding the role of TAng in CTD-ILD+ is available.Objectives:To study, for the first time, the potential role of TAng related to vascular damage in CTD-ILD+.Methods:Peripheral venous blood was collected from 40 patients with CTD-ILD+ and three comparative groups: 44 CTD-ILD- patients, 21 idiopathic pulmonary fibrosis (IPF) patients and 20 healthy controls (HC). All subjects were recruited from the Rheumatology and Pneumology departments of Hospital Universitario Marqués de Valdecilla, Santander, Spain. Quantification of TAng was performed by flow cytometry. TAng were considered as triple-positive for CD3, CD31 and CXCR4.Results:Patients with CTD-ILD+ exhibited a significantly lower TAng frequency than CTD-ILD- patients (p<0.001). Similar results were obtained when patients with CTD-ILD+ were compared with HC (p=0.004) although no difference was observed between CTD-ILD+ and IPF. In addition, a significant increase of TAng frequency was shown in patients with CTD-ILD- in relation to IPF patients (p<0.001), while no difference was observed between CTD-ILD- and HC.Conclusion:Our results reveal a decrease of TAng frequency related to vascular damage in CTD-ILD+. Furthermore, we disclose that the presence of ILD is associated with lower TAng frequency.References:[1]Expert Rev Clin Immunol 2018;14(1):69-82.[2]Circulation 2007;116(15):1671-82.[3]Ann Rheum Dis 2015 74(5):921-7.[4]PLoS One 2017;12(8):e0183102.Acknowledgements:Personal funds, VP-C: PREVAL18/01 (IDIVAL); SR-M: RD16/0012/0009 (ISCIII-ERDF); LL-G: INNVAL20/06 (IDIVAL); RP-F: START PROJECT (FOREUM); RL-M: Miguel Servet type I CP16/00033 (ISCIII-ESF).Disclosure of Interests:Verónica Pulito-Cueto: None declared, Sara Remuzgo Martinez: None declared, Fernanda Genre: None declared, Belén Atienza-Mateo: None declared, Victor Manuel Mora-Cuesta: None declared, David Iturbe-Fernández: None declared, Leticia Lera-Gómez: None declared, Raquel Pérez-Fernández: None declared, Pilar Alonso Lecue: None declared, Javier Rodriguez Carrio: None declared, Diana Prieto-Peña: None declared, Virginia Portilla: None declared, Ricardo Blanco Speakers bureau: Abbvie, Pfizer, Roche, Bristol-Myers, Janssen and MSD, Consultant of: Abbvie, Pfizer, Roche, Bristol-Myers, Janssen and MSD, Grant/research support from: Abbvie, MSD and Roche, Alfonso Corrales: None declared, Jose Manuel Cifrián-Martínez: None declared, Raquel López-Mejías: None declared, Miguel A González-Gay Speakers bureau: Pfizer, Abbvie, MSD, Grant/research support from: Pfizer, Abbvie, MSD
33
Endocrinología, Diabetes & Metabolismo, Asociación Colombiana de. "Diabetes y Obesidad." Revista Colombiana de Endocrinología, Diabetes & Metabolismo 2, no. 2 (2017): 66–75. http://dx.doi.org/10.53853/encr.2.2.83.
Full textAbstract:

 Correlación entre los valores de la glucemia basal y la prueba de tolerancia oral a la glucosa (PTOG) en niños con sobrepeso Awadalla Shokery
 Prevalencia y factores asociados a la resistencia a la insulina en adultos mayores de 20 años en Barranquilla, 2013 Alvarez, L. Angarita, C. Arjona, D. Cabarcas, C. Molina, L. Navarro, E.
 Mejoría de los niveles de HDL y triglicéridos en pacientes con enfermedad coronaria sometidos a ejercicio físico Ávila JC; Betancourt-Peña J.
 Tamizaje poblacional para la detección de trastornos del metabolismo de la glucosa en los afiliados de la EPS Mutual Ser Barengo, NC, Tamayo, DC, Jerez Arias, M, Olivo de Arco, O, Mercado Arias, G, Vega, D, Paz, J, Tono T
 La actividad física grupal impacta positivamente la calidad de vida en las personas con diabetes mellitus tipo 2 Barrera AE, Pérez NB, López EC, Rico AF
 Comportamiento de la diabetes mellitus en Centros de Medicina Familiar Barreto Quintana Helen María, Kim Kyung Hwa, Sáenz Castro Víctor Alexander
 Frecuencia de dislipidemia y relación con enfermedad tiroidea en agricultores. Quindío, Colombia Bayona A, Restrepo B, Landázuri P, Londoño AL, Sánchez JF, Moreno P, Cubillos J, Martínez AD.
 Correlación entre niveles de colesterol LDL medido, comparado con el colesterol LDL calculado por la fórmula de Friedewald en una población de Medellín Builes-Montaño CE, Londoño MP, Aristizábal N, RománGonzáles A, Echavarría E, Posada S, Henao A, Toro JM
 Caracterización clínica-bioquímica de factores de riesgo cardiovascular en la población joven de Cartagena Cabarcas O, Pulgar M, Alvear C
 Encuesta sobre los patrones de práctica clínica en el manejo del paciente diabético en hospitales de tercer nivel en Medellín, Colombia Daguer S, Hincapié J, Ramírez-Rincón A, Palacio A, Botero JF.
 Perfil epidemiológico de la población que asiste al programa de riesgo cardiovascular de Redsalud ESE, Armenia, Quindío, 2013-2014 Duque JL, Orozco P, Lasso JP, Escobar L, Borja A.
 Síndrome metabólico en pacientes adultos con diabetes mellitus tipo 2 asistentes al programa de control en tres hospitales públicos de Colombia Forero Y, Rodríguez S, Romero J.
 Impacto clínico en expectativa de vida y complicaciones crónicas de pacientes diabéticos tipo 1 usuarios de terapia con bomba de insulina integrada a sistema de monitoreo continuo de glucosa Gómez AM, Mora E, Colon C, Fonseca C.
 Terapia con bomba de insulina integrada a monitoreo continuo de glucosa en el tratamiento de pacientes con diabetes mellitus tipo 2 y su impacto sobre la hipoglucemia Ana María Gómez
 Embolización de metástasis hepáticas en insulinoma maligno: de la hipoglucemia a la hiperglucemia. Reporte de un caso González A.M., Vallejo S., López A., Rojas L.J. Fierro L.F. Quintana J.L. y Cuéllar A.A.
 Coaching en diabetes: exploración de resultados clínicos Hincapié J, Laiton E, Bedoya J, Hincapié L, Galeano M, Hincapié G, Botero JF, Palacio A.
 Actividad enzimática de paraoxonasa 1 en trabajadores del sector agrícola del departamento del Quindío Landazuri P., Ojeda J.A.
 La atención integral especializada reduce notablemente los costos directos de la diabetes mellitus tipo 2 (DM2) López E.C, Blanco C S, Barrera AE., Rico A.F.
 Comportamiento de la prediabetes en pacientes masculinos con riesgo de diabetes mellitus atendidos en el INEM Irasel Martínez Montenegro MD, Msc
 La circunferencia de la cintura es un parámetro clínico útil para identificar alteraciones en el metabolismo de los carbohidratos Irasel Martínez
 Plasmaféresis para hipertrigliceridemia severa en el embarazo Navarro EP, Zapata D, Feriz KM, Guzmán GE, Adams CD
 Metaloproteinasas y leptina en conductores de vehículos de servicio público con síndrome metabólico en Armenia, Quindío Nieto-Cárdenas OA
 Grado de control glucémico en pacientes diabéticos con historia de infarto que no han presentado un segundo evento cardiovascular Pérez, M, Rivera F., Prieto A., Duque R.
 Resultados de hipoglucemias severas a un año en pacientes con infusión subcutánea continua de insulina y monitoreo de glucosa en tiempo real Ramírez-Rincón A, Hincapié J, Aristizábal N, Monsalve C, Delgado R, Zapata E, Hincapie G, Castillo E, Mesa P, Vázquez M, Palacio A, Botero JF
 Prevalencia y factores asociados de obesidad y sobrepeso en estudiantes y docentes de la Universidad del Cauca, 2014 Ramos OA, Arango C., Orozco P., Idrobo L., Pantoja L., Narváez D., López G. 
 Diabetes mellitus en Colombia en el último quinquenio: tasas de reporte en las fuentes oficiales de información Tamayo, DC., Barengo, NC.
 
34
PAZ Y MIÑO CONDE, MANUEL ABRAHAM. "Gutiérrez Gómez, Edgar (2012). El absurdo de la vida. Ayacucho (Perú): copygraph Bautista, 129 pp." PURIQ 1, no. 01 (2019): 129–35. http://dx.doi.org/10.37073/puriq.1.01.17.
Full textAbstract:
Como toda expresión humana, el sentido de la vida se puede abordar de modo optimista o pesimista. Sobre el primer modo, tenemos los libros de: a) Juan A. Mackay, filósofo y teólogo presbiteriano escocés, El sentido de la vida y otros ensayos de 1978 (3ra. ed.), donde habla en realidad del sentido de la hombridad, la vocación, la verdad, la amistad, el universo y lo cristiano; el autobiográfico de Moisés Chávez Ramos, escritor y hebraísta evangélico, Filosofía de la vida (s/f) donde concibe a esta “como la búsqueda del propósito y del sentido de la vida” (p. 7). b) Ángel Peña Benito, sacerdote agustino, Vale la pena vivir de 2006, quien afirma que “(e)l sentido de la vida está en Dios, que nos ama, aunque, a veces, esté oculto y silencioso” (p. 4).
35
Prieto-Peña, D., M. Calderón-Goercke, A. Adan, et al. "AB1055 CERTOLIZUMAB PEGOL: A SAFE AND EFFICIENT TREATMENT IN PATIENTS WITH UVEITIS DURING PREGNANCY." Annals of the Rheumatic Diseases 79, Suppl 1 (2020): 1817.1–1818. http://dx.doi.org/10.1136/annrheumdis-2020-eular.1610.
Full textAbstract:
Background:Anti-TNFα agents are useful in uveitis(1-5).Certolizumab pegol (CZP) differs from other anti-TNFα agents due to its limited placental transfer.Objectives:To assess efficacy and safety of CZP in women with uveitis during pregnancy.Methods:Multicenter study of women with uveitis under CZP during pregnancy and their neonates.Results:14 women (23 eyes); mean age 34.3±5.5 yrs (TABLE 1). Pattern of uveitis: 10 anterior, 2 posterior, 1 intermediate, 1 panuveitis. Uveitis was bilateral in 9 and chronic in 7. CZP was started before conception in 10 patients and after in 4. All patients obtained or maintained ocular remission throughout pregnancy (FIGURE). Prednisone was reduced from a mean dose of 21.7±19.7 mg/day to 4.1±3.8 mg/day at 6 months (p=0.03), leading to complete discontinuation in 4. 15 healthy infants were born. Only 1 woman presented a mild infection. No infections or malformations were found in neonates after a follow-up of 6 months. 6 infants were breastfed and all received scheduled vaccinations without complications (TABLE 2).TABLE 1.AgeUnderlying diseaseImmunosuppressants before CZPCombined treatment134SpAMTX, AZA, ADAAZA237SpAMTX, AZA, IFX, ADA, GOLI339SpAAZA, ADAAZA446SpACyA, ETN, ADA, IFX, GOLI532SpASSZ, ADASSZ636SpAMTX, HCQ, ADA740SpAMTX, LFN, HCQ, IFX, ADA, GOLIHCQ831IdiopathicMTX, MMF, CyA, ADA933IdiopathicMTX, AZA, ADA, ETN1032RAMTXAZA1123Vogt-Koyanagi-HaradaAZA, ADAAZA1236Juvenil Idiopathic ArthritisADA1332Punctate inner choroidopathyADA1429BehcetCyA, IFX, ADAConclusion:CZP seems to be effective and safe in female patients with uveitis during pregnancy and neonates.References:[1]Llorenç V et al. Certolizumab Pegol, a New Anti-TNF-α in the Armamentarium against Ocular Inflammation. Ocul Immunol Inflamm. 2016;24(2):167-72. doi: 10.3109/09273948.2014.967779[2]Urruticoechea-Arana A et al. Efficacy and safety of biological therapy compared to synthetic immunomodulatory drugs or placebo in the treatment of Behçet’s disease associated uveitis: a systematic review. Rheumatol Int. 2019 Jan;39(1):47-58. doi: 10.1007/s00296-018-4193-z[3]Martín-Varillas JL et al. Successful Optimization of Adalimumab Therapy in Refractory Uveitis Due to Behçet’s Disease Ophthalmology. 2018 Sep;125(9):1444-1451. doi: 10.1016/j.ophtha.2018.02.020[4]Santos-Gómez M et al. The effect of biologic therapy different from infliximab or adalimumab in patients with refractory uveitis due to Behçet’s disease: results of a multicentre open-label study. Clin Exp Rheumatol. 2016. Sep-Oct;34(6 Suppl 102): S34-S40[5]Calvo-Río V et al. Golimumab in refractory uveitis related to spondyloarthritis. Multicenter study of 15 patients.Semin Arthritis Rheum. 2016 Aug;46(1):95-101. doi: 10.1016/j.semarthrit.2016.03.002Disclosure of Interests:D. Prieto-Peña: None declared, Monica Calderón-Goercke: None declared, Alfredo Adan: None declared, Lillian Chamorro-López: None declared, Olga Maiz: None declared, JR De Dios-Jiménez Aberásturi: None declared, Raul Veroz Gonzalez: None declared, Soledad Blanco: None declared, José M Santos: None declared, Francisco Navarro: None declared, Adela Gallego: None declared, Senen González-Suárez: None declared, Arantxa Conesa: None declared, Andrea García-Valle: None declared, Miguel Cordero-Coma: None declared, Nieves Pardiñas-Barón: None declared, Rosalía Demetrio-Pablo: None declared, Vanesa Calvo-Río Grant/research support from: MSD and Roche, Speakers bureau: AbbVie, Lilly, Celgene, Grünenthal, UCB Pharma, Victor Manuel Mora-Cuesta: None declared, Santos Castañeda: None declared, J. Luis Hernández: None declared, Miguel A González-Gay Grant/research support from: Pfizer, Abbvie, MSD, Speakers bureau: Pfizer, Abbvie, MSD, Ricardo Blanco Grant/research support from: AbbVie, MSD, Roche, Consultant of: Abbvie, Eli Lilly, Pfizer, Roche, Bristol-Myers, Janssen, UCB Pharma and MSD, Speakers bureau: Abbvie, Eli Lilly, Pfizer, Roche, Bristol-Myers, Janssen, UCB Pharma. MSD
36
Sanchez-Bilbao, L., D. Martinez-Lopez, B. Atienza-Mateo, et al. "FRI0504 TOCILIZUMAB IN GRAVES’ ORBITOPATHY. MULTICENTER STUDY OF 48 PATIENTS." Annals of the Rheumatic Diseases 79, Suppl 1 (2020): 850–51. http://dx.doi.org/10.1136/annrheumdis-2020-eular.3651.
Full textAbstract:
Background:Tocilizumab (TCZ) has shown promising results in the treatment of inflammatory ocular disease, especially in uveitis (1-3). Graves orbitopathy (GO) is the most common complication of Graves’ disease (GD). Conventional immunosuppressive drugs are not always effective or well tolerated. TCZ may be useful in the treatment of GO.Objectives:To assess the efficacy of TCZ in corticoid-resistant GO.Methods:Multicenter open study of corticoid-resistant GO. We measured clinical activity using the clinical activity score (CAS). CAS evaluates 10 different ocular items, ranging from 0 (no symptoms) to 10. We defined remission as the presence of CAS ≤ 3.Results:We studied 48 (95 eyes) patients (TABLE). Besides oral corticosteroids, they had received iv Methylprednisolone (n=43), methimazole (n=20), selenium (n=11) or radioactive iodine (n=5). According to the classification of severity (EUGOGO group), before of TCZ onset our patients had severe (n=19) or moderate (n=29) disease. TCZ was used in monotherapy (n=45) or combined with methotrexate (n=2) or azathioprine (n=1) at a dose of 8 mg/kg/iv/4 weeks (n=43) or 162 mg/sc/week (n=5). TCZ yielded rapid and maintained improvement and most patients achieved remission (FIGURE).TABLE:Number of patients/eyes affected, n/n48/96Age, mean (SD), years50.96 (11.78)Sex, men/women, n/n (%)10/38 (20.8 / 79.2)Regimen of TCZ therapyMonotherapy/combined treatment, n (%)45/3 (93.8/6.2)• AZA1 (2.1)• MTX2 (4.2)TCZ dosage, n (%)• 8 mg/kg/iv/4 weeks43 (89.6)• 162 mg/sc/week5 (10.4)Follow-up on TCZ therapy, mean (SD), months16.05±2.06• Remission, n (%)72 (75.8)• Discontinuation treatment, n (%)29 (60.4) • Remission25 (86.2) • Inefficacy4 (13.8) • Side effects0FIGURE:After a mean follow-up of 16.1±2.1 months, most patients experienced ocular improvement, with TCZ withdrawal in 29 cases due to remission (n=25) or inefficacy (n=4). Only 5 relevant adverse events were observed (neutropenia, external otitis, otitis media, costal osteitis and gingival hyperplasia). None of these events resulted in discontinuation of the treatment.Conclusion:TCZ appears to be an effective and safe treatment in corticoid-resistant GO.References:[1] Santos-Gómez M, et al. Clin Exp Rheumatol 2016; 34 Suppl 102(6):34-40[2] Calvo-Río V, et al. Clin Exp Rheumatol. 2014; 32 (4 Suppl 84): S54-7[3] Vegas-Revenga N et al. Am J Ophthalmol. 2019 Apr; 200:85-94.Disclosure of Interests:Lara Sanchez-Bilbao Grant/research support from: Pfizer, David Martinez-Lopez: None declared, Belén Atienza-Mateo: None declared, José Luis Martín-Varillas Grant/research support from: AbbVie, Pfizer, Janssen and Celgene, Speakers bureau: Pfizer and Lilly, Vanesa Calvo-Río Grant/research support from: Abbvie, Lilly, UCB, MSD, Cellgene, Speakers bureau: Abbvie, Lilly, UCB, MSD, Cellgene, Rosalía Demetrio-Pablo: None declared, Monica Calderón-Goercke: None declared, D. Prieto-Peña: None declared, Iñigo González-Mazón: None declared, Elia Valls-Pascual Grant/research support from: Roche, Novartis, and AbbVie, Speakers bureau: AbbVie, Lilly, Pfizer, MSD, Novartis, Janssen, Bristol Myers Squibb, UCB Pharma, Beatriz Valls-Espinosa: None declared, Olga Maiz-Alonso: None declared, Ana Blanco Speakers bureau: Abbvie, Ignacio Torre-Salaberri: None declared, Verónica Rodriguez-Mendez: None declared, Ángel García-Aparicio: None declared, Raúl Veroz González: None declared, Vega Jovani: None declared, Diana Peiteado Grant/research support from: AbbVie, Lilly, MSD, and Roche, Speakers bureau: AbbVie, Roche, and MSD, Santos Castañeda: None declared, Margarita Sánchez-Orgaz: None declared, Eva Tomero Muriel: None declared, Francisco J. Toyos Sáenz de Miera: None declared, Valvanera Pinillos: None declared, Elena Aurrecoechea: None declared, Ángel Mora: None declared, Arantxa Conesa: None declared, Manuel Fernández: None declared, J. Antonio Troyano: None declared, Marcelino Revenga: None declared, J. Luis Hernández: None declared, Miguel A González-Gay Grant/research support from: Pfizer, Abbvie, MSD, Speakers bureau: Pfizer, Abbvie, MSD, Ricardo Blanco Grant/research support from: AbbVie, MSD, and Roche, Speakers bureau: AbbVie, Pfizer, Roche, Bristol-Myers, Janssen, and MSD
37
Diabetes y Metabolismo, Asociación Colombiana de Endocrinología. "Diabetes." Revista Colombiana de Endocrinología, Diabetes & Metabolismo 6, no. 2S (2019): 67–76. http://dx.doi.org/10.53853/encr.6.2s.506.
Full textAbstract:
Listado:
 
 Adulto mayor con diabetes y caídas a repetición: factores asociados, análisis secundario del estudio SABE Colombia. Morros E, Venegas LC, Vargas MP, Chacón E, Chavarro D, Cano CA.
 Análisis comparativo entre pruebas clínicas y pruebas electrofisiológicas para la detección de neuropatía diabética en pacientes del servicio electrodiagnóstico de la Clínica Somefyr en 2018. Pineda LO, Peña AA, Monroy MA.
 Conocimiento, tratamiento y control de la diabetes mellitus tipo 2 en colombianos de 35-70 años: estudio PURE. García LM1 , Alvernia MJ1 , Camacho PA1 , Uribe S2 , Pérez M2 , López P1
 Consumo de hipoglucemiantes en pacientes con diabetes mellitus tipo 2 en la costa atlántica colombiana. Fernández JC, Orjuela LT, Ospina JD, Amézquita MA
 Determinantes de la prevalencia de prediabetes y diabetes mellitus tipo 2 en Colombia: estudio PURE. Alvernia MJ1 , García M1 , Camacho PA1 , Uribe S2 , Pérez M2 , López P1.
 Dulaglutide Has Higher Adherence and Persistence Than Liraglutide and Exenatide OnceWeekly: 1-Year Follow-Up from United States Real-World Data. Landó LF1 , Mody R1 , Huang Q2 , Yu M3 , Zhao R2 , Patel H1 , et al.
 Efecto hipoglucemiante de Anacardium occidentale L como posible tratamiento en pacientes con diabetes mellitus. Parga CH, Tapia AD, Botero AC, Brito JE, De las Salas M, Fruto AC, et al.
 Efecto de una intervención educativa en el conocimiento de la enfermedad del paciente con diabetes mellitus hospitalizado. Rojas N, Saldarriaga M, Builes CE, Arango CM, Prieto C, Jaramillo C.
 Gestión individualizada del riesgo en población diabética de Javesalud: experiencia de atención centrada en la persona en cuidado ambulatorio. Gordon SG, Páez PL, Castro DF, Robayo CX.
 Hiperglucemia severa de difícil manejo: síndrome de resistencia a los análogos de insulina. Pino JJ, Monsalve C, Aristizábal N
 Lesser Estimated Glomerular Filtration Rate Decline with Dulaglutide Regardless of Weight Changes in People with Type 2 Diabetes and Moderate to Severe Chronic Kidney Disease. Tuttle KR1 , Lakshmanan MC2 , Rayner B3, Busch RS4 , Zimmermann AG2 , Woodward BD2 , et al.
 Modelo matemático de la homeostasis de la glucosa: una mirada al comportamiento de pacientes con diabetes tipo 1. Ruiz N1 , Colorado V1 , Lema L1 , Builes CE2
 Modelo semifísico de base fenomenológica del rol del páncreas en la homeostasis de la glucosa en humanos. Dávila MA1 , Tutalcha HA1 , Lema L1 , Builes CE2
 Nivel de adherencia a los tratamientos no farmacológicos de pacientes con diabetes mellitus, Barranquilla, 2017. Amador E, Montealegre L, Arteta M, De Oro C, Navarro G.
 Niveles de vitamina B12 en pacientes con diabetes mellitus en tratamiento con metformina. Gómez JM, Laverde LA, González S, Penagos K, Rincón P, Tafurt Y.
 Prediabetes, una condición frecuente en el ámbito hospitalario. Mejía HJ, Figueroa CL, Rodríguez RM, Romero DG, Gualdrón V, Sánchez D, et al.
 Registro colombiano de pacientes con diabetes tipo 2. Reynales H, Castaño DM
 Relación entre la severidad del síndrome de apnea-hipopnea del sueño (SAHOS) y la diabetes mellitus tipo 2 (DM2). Mendoza T1,2, Parra LA2, 3, 4.
 Resultados en hospitalización y mortalidad por causa médica de la adherencia al tratamiento farmacológico en pacientes con diabetes mellitus tipo 2. Guzmán G1 , Iriarte MB2 , Ortega S2 , Ortiz D2 , Pardo N2 , Plaza E2 , et al.
 Trasplante único de páncreas para paciente diabética tipo 1: reporte de un caso. Guzmán GE1, 2, Martínez V1, 2, Durán CE 2,3 Manzi E 4 , Mesa L3 , Schweineberg J3 , et al.
 Uso de agonistas del receptor de GLP1 para el tratamiento de la diabetes mellitus: experiencia de la vida real. Builes CE, Rojas N, Prieto C, Arango CM, Gutiérrez J, Saldarriaga M, et al.
38
Prieto-Peña, D., M. Calderón-Goercke, I. Martínez-Rodríguez, et al. "SAT0568 PERSISTENT VASCULAR 18F-FDG UPTAKE DESPITE CLINICAL-ANALYTICAL REMISSION IN PATIENTS WITH LARGE VESSEL VASCULITIS UNDER TOCILIZUMAB THERAPY. SINGLE UNIVERSITARY CENTER EXPERIENCE OF 30 PATIENTS." Annals of the Rheumatic Diseases 79, Suppl 1 (2020): 1242.1–1242. http://dx.doi.org/10.1136/annrheumdis-2020-eular.1628.
Full textAbstract:
Background:Tocilizumab (TCZ) has shown efficacy in large vessel vasculitis (LVV)(1-3). Disease activity assessed by laboratory markers (ESR,CRP) may be of less value with TCZ.18F-FDG PET/CT may be useful to monitor LVV disease activity(4-5).Objectives:To assessa) evolution of disease activity in LVV treated with TCZ by PET/CT andb) its correlation with clinical/serological markers.Methods:Single centre study of 30 patients with refractory LVV treated with TCZ who had a baseline and follow-up PET/CT scan. Vascular uptake was assessed quantitatively and qualitatively. Quantitative analysis was assessed as a target to background ratio (TBR)=SUVmax thoracic aorta/SUVmax aortic vascular pool. For qualitative analysis, FDG uptake at vessel wall was visually grading compared to the liver. We defined a total vascular score which included 5 vascular areas (supra aortic trunks, thoracic, abdominal, iliac and femorotibial arteries) ranging from 0 to 15. Clinical improvement (no improvement/partial/complete), analytical (CRP mg/dL; ESR mm/1sthour) and reduction of prednisone dose (mg/day) were also assessed.Results:30 patients (24 w/6 m); mean age 65.3 ± 10.6 yrs. TCZ was started after 6.5 [2.0-20.0] months from LVV diagnosis. Most patients received TCZ as intravenous infusions (70%) and almost half of them (46.7%) received combined therapy with MTX. Clinical/analytical evolution and quantitative/qualitative uptake assessment is shown inTABLE. After a mean follow-up of 37.0±18.5 months, 92.3% of patients experienced complete clinical/analytical improvement. Complete quantitative normalization of vascular uptake (TBR< 1.34) was achieved in 30.8%. Qualitatively, 23.1% of patients showed normalization (total vascular score =0) at the end of the study period.Conclusion:Most patients with LVV under TCZ experienced rapid and effective clinical and analytical response. Decrease of vascular uptake was also observed both quantitatively and qualitatively assessed. However, complete normalization of vascular uptake despite clinical remision was only observed in less than one-third of patients.TABLE.Basal(n=30)6 months(n=9)12-18 months(n=21)>18 months(n=13)Clinical improvementComplete,n (%)7 (77.8)16 (76.2)12 (92.3)Laboratory markersESR (mm/1sth),median [IQR]24.0 [9.8-53.0]2.0 [2.0-3.0] *2.0 [2.0-4.0] *2.0[2.0-3.5] *CRP (mg/dL),median [IQR]1.5 [0.5-2.4]0.1 [0.1-0.2] *0.1 [0.1-0.1] *0.1 [0.1-0.1] *ESR/CRP normalization, n(%)9 (100)21 (100)13 (100)FDG vascular uptakeTBR,mean ± SD1.69 ± 0.521.56±0.41 *1.46±0.16 *1.40 ± 0.18 *Total vascular score,mean ± SD5.0 ± 2.63.7 ± 2.23.3 ± 1.7*2.7 ± 2.4*Quantitative normalization, n(%)4 (44.4)5 (23.8)4 (30.8)Qualitative normalization, n(%)1 (11.1)1 (4.8)3 (23.1)*test Wilcoxon: p < 0.05. Quantitative normalization when TBR <1.34. Qualitative normalization when total vascular score =0.References:[1]Calderón-Goercke M et al. Tocilizumab in giant cell arteritis. Observational, open-label multicenter study of 134 patients in clinical practice. Semin Arthritis Rheum. 2019 Aug; 49(1):126-135. doi: 10.1016/j.semarthrit.2019.01.003.[2]Loricera et al. Tocilizumab in patients with Takayasu arteritis: a retrospective study and literature review. Clin Exp Rheumatol. 2016 May-Jun;34(3 Suppl 97): S44-53.[3]González-Gay MA et al. Current and emerging diagnosis tools and therapeutics for giant cell arteritis. Expert Rev Clin Immunol. 2018 Jul;14(7):593-605. doi: 10.1080/1744666X.2018.1485491.[4]Martínez-Rodríguez et al. (18)F-FDG PET/CT in the follow-up of large-vessel vasculitis: A study of 37 consecutive patients. Semin Arthritis Rheum.2018 Feb;47(4):530-537. doi: 10.1016/j.semarthrit.2017.08.009.[5]Loricera et al. Non-infectious aortitis: a report of 32 cases from a single tertiary centre in a 4-year period and literature review. Clin Exp Rheumatol. 2015 Mar-Apr; 33(2 Suppl 89): S-19-31.Disclosure of Interests:D. Prieto-Peña: None declared, Monica Calderón-Goercke: None declared, Isabel Martínez-Rodríguez: None declared, Jose Ignacio Banzo: None declared, Javier García-Fernández: None declared, Patricia Vicente-Gómez: None declared, Miguel A González-Gay Grant/research support from: Pfizer, Abbvie, MSD, Speakers bureau: Pfizer, Abbvie, MSD, Ricardo Blanco Grant/research support from: AbbVie, MSD, Roche, Consultant of: Abbvie, Eli Lilly, Pfizer, Roche, Bristol-Myers, Janssen, UCB Pharma and MSD, Speakers bureau: Abbvie, Eli Lilly, Pfizer, Roche, Bristol-Myers, Janssen, UCB Pharma. MSD
39
Prieto-Peña, D., M. Calderón-Goercke, P. Bernabéu, et al. "SAT0270 TOCILIZUMAB IN REFRACTORY TAKAYASU ARTERITIS. OPEN-LABEL NATIONAL MULTICENTER STUDY OF 53 PATIENTS OF CLINICAL PRACTICE." Annals of the Rheumatic Diseases 79, Suppl 1 (2020): 1078.2–1079. http://dx.doi.org/10.1136/annrheumdis-2020-eular.2445.
Full textAbstract:
Background:Tocilizumab (TCZ) was recently approved for Takayasu Arteritis (TAK) in Japan based on the results of the TAKT trial(1).However, data in clinical practice in Europe and America are scarce(2).Objectives:To assess efficacy and safety of TCZ in TAK of clinical practice in Spain.Methods:Observational, open-label multicentre study of 53 TAK patients treated with TCZ due to refractoriness or adverse events of previous therapy. Outcomes variables were improvement of clinical features, acute phase reactants and glucocorticoid-sparing effect.Results:53 patients (46w/7m); mean age, 40.6±14.6 years at TCZ onset. TCZ was started after a median of 12 [3.0-48.0] months from TAK diagnosis. In addition to systemic corticosteroids and before TCZ they received conventional immunosuppressant drugs (n=42) and biologic therapy (n=14). TCZ was prescribed as standard I.V. (n=42; 79.2%) or subcutaneous (n=11; 20.8%). The initial dose was 8 mg/kg/IV/4 weeks or 162 mg/SC/week, respectively. TCZ was used in monotherapy or combined with immunosuppressants (n=32; 60.4%): methotrexate (n=27), azathioprine (n=2), cyclosporine (n=3). Main clinical features at TCZ onset were: malaise (n=30),limb claudication (n=22), headache (n=18), fever (n=14), abdominal pain (n=10), and chest pain (n=9). Most of the patients experienced a rapid and maintained clinical, analytical improvement(TABLE).After a median follow-up of 18.0 [7.0-45.0] months, TCZ was discontinued in 20 patients due to: sustained remission (n=6), relapse (n=6), adverse event (n=5), gestation (n=3). Most relevant adverse side effects were serious infections: pneumonia (n=2), herpes zoster (n=1), abdominal sepsis (n=1).Table.Basal(N=53)Month 1(N=53)Month 3(N=46)Month 6(N=44)Month 12(N=34)Clinical improvement, n/N(%)Complete17/53 (32.1)19/46 (41.3)23/44 (52.3)26/34 (76.5)Partial30/53 (54.6)26/46 (56.5)18/44 (40.9)8/34 (23.5)No improvement6/53 (11.3)1/46 (2.2)3/44 (6.8)0/34 (0.0)Analytical markers,ESR (mm/1sth),median [IQR]35.0 [16.0-52.0]7.5 [3.0-14.0] *3.5 [2.0-8.0]*5.0[2.0-6.0]*5.0 [2.0-8.5]*CRP (mg/dL),median [IQR]1.7 [0.6 -3.5]0.21 [0.05-0.6]*0.14 [0.05-0.5]*0.14 [0.04-0.4]*0.10 [0.03-0.30]*Hb (g/dL),mean±SD12.3±1.512.8±1.2*12.9±1.3*12.9±1.4*12.9±1.4*Prednisone dose (mg/day),median [IQR]30.0 [15.0-50.0]20.0 [10.0-37.5]*10.0 [5.0-20.0]*5.0 [5.0-12.5]*5.0 [0.0-7.5]**Wilcoxon test p < 0.001.Conclusion:TCZ appears to be effective and safe in patients with refractory TAK in clinical practice.References:[1]Nakaoka Y et al. Ann Rheum Dis. 2018;77:348-354[2]Loricera J et al. Clin Exp Rheumatol. 2016; 34: S44-53.Disclosure of Interests:D. Prieto-Peña: None declared, Monica Calderón-Goercke: None declared, Pilar Bernabéu: None declared, Paloma Vela-Casasempere: None declared, J. Narváez: None declared, Carlos Fernández-López: None declared, Mercedes Freire González: None declared, Beatriz González-Alvarez: None declared, Roser Solans-Laqué: None declared, Jose Luis Callejas-Rubio: None declared, Norberto Ortego: None declared, Carlos Fernández-Díaz Speakers bureau: Brystol Meyers Squibb, Esteban Rubio Romero: None declared, SALVADOR GARCÍA MORILLO: None declared, Mauricio Minguez: None declared, Cristina Fernández-Carballido Consultant of: Yes, I have received fees for scientific advice (Abbvie, Celgene, Janssen, Lilly and Novartis), Speakers bureau: Yes, I have received fees as a speaker (Abbvie, Celgene, Janssen, Lilly, MSD, Novartis), Eugenio de Miguel Grant/research support from: Yes (Abbvie, Novartis, Pfizer), Consultant of: Yes (Abbvie, Novartis, Pfizer), Paid instructor for: yes (AbbVie, Novartis, Pfizer, MSD, BMS, UCB, Roche, Grunental, Janssen, Sanofi), Speakers bureau: yes (AbbVie, Novartis, Pfizer, MSD, BMS, UCB, Roche, Grunental, Janssen, Sanofi), Sheila Melchor: None declared, Eva Salgado-Pérez: None declared, Beatriz Bravo: None declared, Susana Romero-Yuste: None declared, J Salvatierra: None declared, Cristina Hidalgo: None declared, Sara Manrique Arija: None declared, C. Romero-Gómez: None declared, Patricia Moya: None declared, Noelia Alvarez-Rivas: None declared, Javier Mendizabal: None declared, Francisco Miguel Ortiz Sanjuan: None declared, I. Pérez de Pedro: None declared, Javier Loricera: None declared, Santos Castañeda: None declared, Miguel A González-Gay Grant/research support from: Pfizer, Abbvie, MSD, Speakers bureau: Pfizer, Abbvie, MSD, Ricardo Blanco Grant/research support from: AbbVie, MSD, Roche, Consultant of: Abbvie, Eli Lilly, Pfizer, Roche, Bristol-Myers, Janssen, UCB Pharma and MSD, Speakers bureau: Abbvie, Eli Lilly, Pfizer, Roche, Bristol-Myers, Janssen, UCB Pharma. MSD
40
Prieto-Peña, D., M. Calderón-Goercke, I. Martínez-Rodríguez, et al. "FRI0215 RESPONSE TO TOCILIZUMAB IN LARGE VESSEL VASCULITIS ACCORDING TO THE EXTENT OF BASELINE 18F-FDG VASCULAR UPTAKE." Annals of the Rheumatic Diseases 79, Suppl 1 (2020): 691.1–691. http://dx.doi.org/10.1136/annrheumdis-2020-eular.1624.
Full textAbstract:
Background:18F-FDG PET/CT is useful to establish the presence and extent of large vessel vasculitis (LVV)(1-2).Early therapy is needed to prevent severe complications.Tocilizumab (TCZ) has shown efficacy in LVV(3-5).However, it is unknown if the extent of FDG vascular uptake may influence on clinical response to TCZObjectives:To assess the correlation of the extent of baseline FDG vascular uptake in PET/CT scan with clinical response to TCZ in patients with LVV.Methods:Single center study of patients with LVV treated with TCZ who were divided into 2 groups depending on the extent of vascular uptake in baseline PET/CT scan:a) 1-2 affected areasb) ≥affected 3 areas. Vascular uptake was qualitatively assessed by two experienced nuclear medicine physicians in five areas (supraaortic trunks, thoracic aorta, abdominal aorta, iliac and femorotibial arteries). We assessed clinical improvement (no improvement/partial/complete), normalization of CRP (≤0.5mg/dL) and/or ESR (≤ 20 mm/1sth) and reduction of prednisone dose (mg/day).Results:30 patients (24 w/6 m); mean age 65.3±10.6 yrs. In baseline PET/CT, vascular uptake was observed in 1 or 2 areas (n=13) and in ≥3 areas (n=17). There was a trend to higher ESR/CRP and shorter evolution of clinical symptoms before TCZ onset in patients with ≥3 affected areas (TABLE 1). Clinical/serological evolution and reduction of prednisone dose is shown in TABLE 2. No statistical differences were found. However, patients with ≥ 3 affected areas tended to experience a slower clinical response.TABLE 1.1-2 vascular affected areas (n=13)≥3 vascular affected areas (n=17)PDemographic dataAge,mean ± SD66.0 ± 10.864.8 ± 10.70.77Sex (women),n (%)11 (84.6)13 (76.5)0.67Evolution time before TCZ (months),median [IQR]26.0 [3.5-34.0]5.0 [1.5-10.0]0.02Laboratory markersESR (mm/1st h),mean ± SD30.0 ± 27.334.8 ± 27.60.64CRP (mg/dL),mean ± SD1.3 ± 1.21.8 ± 1.70.28Previous treatmentPrednisone dose (mg/day),mean ± SD9.4 ± 6.27.9 ± 6.90.53TCZ therapyIntravenous, n(%)10 (76.9)11 (64.7)0.47Combined with MTX, n(%)6 (46.2)8 (47.1)0.96TABLE 2.1-2 vascular affected areas (n=13)≥ 3 vascular affected areas (n=17)PComplete clinical improvement,n/N (%)6 m11/13 (84.6)12/17 (70.6)0.4312 m12/13 (92.3)13/17 (76.5)0.3618 m10/11 (90.9)11/12 (91.7)0.9924 m8/8 (100)9/10 (90.0)0.99Normalization of ESR and/or CRP,n/N (%)6 m13/13 (100)16/17 (94.1)0.9912 m13/13 (100)16/17 (94.1)0.9918 m11/11 (100)11/12 (91.7)0.9924 m8/8 (100)10/10 (100)0.99Dose of Prednisone (mg/day),median [IQR]6 m5.0 [1.3-5.0]5.0 [0.0-5.0]0.9812 m2.5 [0.0-3.8]0.0 [0.0-5.0]0.9718 m0.0 [0.0-2.5]0.0 [0.0-1.9]0.7224 m0.0 [0.0- 2.2]0.0 [0.0-2.5]0.77Conclusion:TCZ therapy was effective in patients with LVV regardless the extent of FDG vascular uptake in baseline PET/CT scan. However, a trend to a slower clinical response was observed in patients with ≥3 affected areas.References:[1]Martínez-Rodríguez et al. (18)F-FDG PET/CT in the follow-up of large-vessel vasculitis: A study of 37 consecutive patients. Semin Arthritis Rheum.2018 Feb;47(4):530-537. doi: 10.1016/j.semarthrit.2017.08.009.[2]Loricera et al. Non-infectious aortitis: a report of 32 cases from a single tertiary centre in a 4-year period and literature review. Clin Exp Rheumatol. 2015 Mar-Apr; 33(2 Suppl 89): S-19-31[3]Calderón-Goercke M et al. Tocilizumab in giant cell arteritis. Observational, open-label multicenter study of 134 patients in clinical practice. Semin Arthritis Rheum. 2019 Aug; 49(1):126-135. doi: 10.1016/j.semarthrit.2019.01.003[4]González-Gay MA et al. Current and emerging diagnosis tools and therapeutics for giant cell arteritis. Expert Rev Clin Immunol. 2018 Jul;14(7):593-605. doi: 10.1080/1744666X.2018.1485491.[5]Loricera et al. Tocilizumab in patients with Takayasu arteritis: a retrospective study and literature review. Clin Exp Rheumatol. 2016 May-Jun;34(3 Suppl 97): S44-53.Disclosure of Interests:D. Prieto-Peña: None declared, Monica Calderón-Goercke: None declared, Isabel Martínez-Rodríguez: None declared, Jose Ignacio Banzo: None declared, Patricia Vicente-Gómez: None declared, Javier García-Fernández: None declared, Miguel A González-Gay Grant/research support from: Pfizer, Abbvie, MSD, Speakers bureau: Pfizer, Abbvie, MSD, Ricardo Blanco Grant/research support from: AbbVie, MSD, Roche, Consultant of: Abbvie, Eli Lilly, Pfizer, Roche, Bristol-Myers, Janssen, UCB Pharma and MSD, Speakers bureau: Abbvie, Eli Lilly, Pfizer, Roche, Bristol-Myers, Janssen, UCB Pharma. MSD
41
Calderón-Goercke, M., D. Prieto-Peña, S. Castañeda, et al. "THU0297 SERIOUS INFECTIONS IN 134 PATIENTS WITH GIANT CELL ARTERITIS WITH TOCILIZUMAB IN CLINICAL PRACTICE. FREQUENCY, TYPE AND CLINICAL ASSOCIATIONS." Annals of the Rheumatic Diseases 79, Suppl 1 (2020): 376.1–377. http://dx.doi.org/10.1136/annrheumdis-2020-eular.2583.
Full textAbstract:
Background:Infections are the most common adverse event of Tocilizumab (TCZ) in Giant Cell Arteritis (GCA). In GiACTA study(1),serious infections were observed in 7% (9.6/100 patient-years) of patients who received TCZ weekly. Randomized clinical trials (RCTs) are conducted under highly standardized design excluding some real-world patients. Therefore, adverse events may be underestimated in RCTs. In our series of real-life, serious infections occurred in 11.9% (10.6/100 patient-years)(2).Objectives:In a wide series of GCA of clinical practice treated with TCZ, we assess the frequency, type and predisposing factors of serious infections.Methods:Multicenter study of 134 patients diagnosed with GCA, all of them refractory to conventional therapy, treated with TCZ. Serious infection was considered when a life-threatening infection, fatal, or requiring hospitalization occurred, intravenous antibiotics were required, or the infectious process led to persistent or significant disability.Results:16 of 134 (11.9%, 10.6/100 patient-years) patients developed serious infections during follow-up. The most frequent infections were pneumonia (n=4), urinary tract infection (n=4), and facial herpes zoster (n=2). At TCZ onset, serious infections were more frequent in older patients (74.3±9.6 vs 72.9±8.7 years), with a longer GCA evolution (20 [4.3-45.6] vs 13 [5-29.3] months), with visual manifestations (43.75% vs 17.8%) and a higher dose of prednisone at TCZ onset (30.4±15.5 vs 21.1±16.1 mg/day) (TABLE). Presence of comorbidities were similar in both groups. 13 of the 16 patients who had infections received a dose of prednisone greater than 15 mg/day (16.3/100 patient-years) compared to 3 patients under treatment with less than 15 mg/day of prednisone (4.2/100 patient-years).Conclusion:The age, GCA duration, ocular involvement and the dose of glucocorticoids, at TCZ onset, seem to be predisposing factors related to an increased risk of developing serious infections in GCA patients.References:[1]Stone JH, et al. N Engl J Med. 2017; 377:317-28.[2]Calderón-Goercke M et al. Semin Arthritis Rheum 2019 Aug;49(1): 126-135.TABLESERIOUS INFECTIONS(n=16)WITHOUT SERIOUS INFECTIONS(n=118)pBASAL FEATURES AT TCZ ONSETGENERAL FEATURES Age, years, mean± SD74.3±9.672.9±8.70.552 Sex, female/male n(%)13/388/300.760 Time from GCA diagnosis to TCZ onset (months), median [IQR]20[4.3-45.6]13[5-29.3]0.604COMORBIDITIES Hypertension, n(%)9(56)86(73)0.551 Diabetes, n(%)3(19)39(33)0.677 Chronic kidney disease, n(%)3(19)27(23)0.512CLINICAL FEATURES OF GCA PMR, n(%)9(56.25)64(54.2)0.879 Aortitis, n(%)5(31.25)53(45)0.301 Visual manifestations, n(%)7(43.75)21(17.8)0.017CORTICOSTEROIDS AT TCZ ONSET Prednisone dose mg/d, mean (SD)30.4±15.521.1±16.10.031Disclosure of Interests:Monica Calderón-Goercke: None declared, D. Prieto-Peña: None declared, Santos Castañeda: None declared, Clara Moriano: None declared, Elena Becerra-Fernández: None declared, Marcelino Revenga: None declared, Noelia Alvarez-Rivas: None declared, Carles Galisteo: None declared, Águeda Prior-Español: None declared, E. Galindez: None declared, Cristina Hidalgo: None declared, Sara Manrique Arija: None declared, Eugenio de Miguel Grant/research support from: Yes (Abbvie, Novartis, Pfizer), Consultant of: Yes (Abbvie, Novartis, Pfizer), Paid instructor for: yes (AbbVie, Novartis, Pfizer, MSD, BMS, UCB, Roche, Grunental, Janssen, Sanofi), Speakers bureau: yes (AbbVie, Novartis, Pfizer, MSD, BMS, UCB, Roche, Grunental, Janssen, Sanofi), Eva Salgado-Pérez: None declared, Vicente Aldasoro Speakers bureau: Roche, Abbvie, MSD, UCB, Pfizer, Menarini, Grunenthal, Gebro, Novartis, Janssen, Ignacio Villa-Blanco Consultant of: UCB, Speakers bureau: Novartis, MSD, Lilly, Susana Romero-Yuste: None declared, J. Narváez: None declared, Catalina Gomez-Arango: None declared, Eva Perez-Pampín: None declared, Rafael Melero: None declared, Francisca Sivera: None declared, Carlos Fernández-Díaz Speakers bureau: Brystol Meyers Squibb, Alejandro Olive: None declared, María Álvarez del Buergo: None declared, Luisa Marena Rojas: None declared, Carlos Fernández-López: None declared, Francisco Navarro: None declared, Enrique Raya: None declared, Beatriz Arca: None declared, Roser Solans-Laqué: None declared, Arantxa Conesa: None declared, Carlos Vázquez: None declared, Jose Andrés Román-Ivorra: None declared, Pau Lluch: None declared, Paloma Vela-Casasempere: None declared, Carmen Torres-Martín: None declared, Juan Carlos Nieto Speakers bureau: Pfizer, Abbvie, MSD, Novartis, Janssen, Lilly, Nordic Pharma, BMS, Gebro, FAES Farma, Roche, Sanofi, Carmen Ordas-Calvo: None declared, Cristina Luna-Gomez: None declared, Francisco J. Toyos Sáenz de Miera: None declared, Nagore Fernández-Llanio: None declared, Antonio García: None declared, Carmen González-Vela: None declared, Javier García-Fernández: None declared, Patricia Vicente-Gómez: None declared, Ángel García-Manzanares: None declared, Norberto Ortego: None declared, Francisco Ortiz-Sanjuán: None declared, Montserrat Corteguera: None declared, J. Luis Hernández: None declared, Miguel A González-Gay Grant/research support from: Pfizer, Abbvie, MSD, Speakers bureau: Pfizer, Abbvie, MSD, Ricardo Blanco Grant/research support from: AbbVie, MSD, and Roche, Speakers bureau: AbbVie, Pfizer, Roche, Bristol-Myers, Janssen, and MSD
42
Prieto-Peña, D., F. Genre, S. Remuzgo Martinez, et al. "AB0096 IGA VASCULITIS AND IGA NEPHROPATHY SHARE A SIMILAR IL17A ASSOCIATION PATTERN." Annals of the Rheumatic Diseases 80, Suppl 1 (2021): 1076.3–1077. http://dx.doi.org/10.1136/annrheumdis-2021-eular.766.
Full textAbstract:
Background:IgA vasculitis (IgAV) and IgA nephropathy (IgAN) are inflammatory conditions that share pathogenic and molecular mechanisms [1] and may represent different outcomes of a continuous spectrum of disease [2]. Interleukin (IL)17A has been identified as a common genetic risk locus for several immune-mediated diseases [3, 4].Objectives:To determine whether IgAV and IgAN exhibit a different IL17A association pattern.Methods:Five IL17A tag polymorphisms (rs4711998, rs8193036, rs3819024, rs2275913 and rs7747909) were genotyped in 388 Caucasian patients with IgAV, 99 patients with IgAN and 1,003 sex and ethnically matched healthy controls.Results:No statistically significant differences between patients with IgAV and healthy controls and between patients with IgAN and healthy controls were observed when each IL17A genetic variant was analyzed independently (Table 1). Similarly, IgAV patients exhibited similar genotype and allele IL17A frequencies than those with IgAN (Table 1). Moreover, no genotype or allele differences between IgAV patients who developed nephritis and patients with IgAN were detected. Furthermore, haplotype frequencies were similar in patients with IgAV, IgAV and nephritis and those with IgAN.Table 1.Genotype and allele frequencies of IL17A gene in patients with IgA vasculitis, patients with IgA nephropathy and healthy controls.PolymorphismChangeData set1/11/22/212rs4711998G/AIgAV53.4 (207)38.9 (151)7.7 (30)72.8 (565)27.2 (211)IgAN49.0 (48)42.9 (42)8.2 (8)70.4 (138)29.6 (58)Controls52.7 (529)41.2 (413)6.1 (61)73.3 (1471)26.7 (535)rs8193036T/CIgAV57.0 (221)38.4 (149)4.6 (18)76.2 (591)23.8 (185)IgAN64.3 (63)31.6 (31)4.1 (4)80.1 (157)19.9 (39)Controls60.3 (605)35.2 (353)4.5 (45)77.9 (1563)22.1 (443)rs3819024A/GIgAV44.1 (171)43.3 (168)12.6 (49)65.7 (510)34.3 (266)IgAN39.4 (39)54.5 (54)6.1 (6)66.7 (132)33.3 (66)Controls45.6 (457)44.6 (447)9.9 (99)67.8 (1361)32.2 (645)rs2275913G/AIgAV44.6 (172)43.3 (167)12.2 (47)66.2 (511)33.8 (261)IgAN39.8 (39)53.1 (52)7.1 (7)66.3 (130)33.7 (66)Controls44.8 (449)44.2 (443)11.1 (111)66.8 (1341)33.2 (665)rs7747909G/AIgAV53.9 (209)39.4 (153)6.7 (26)73.6 (571)26.4 (205)IgAN41.1 (39)54.7 (52)4.2 (4)68.4 (130)31.6 (60)Controls53.0 (532)39.4 (395)7.6 (76)72.7 (1459)27.3 (547)Conclusion:Our results revealed that IgAV and IgAN share a similar IL17A association pattern.References:[1]N Engl J Med 2013;368:2402-14.[2]Am J Kidney Dis 1988;12:373-7.[3]Ann Rheum Dis 2014;73:1742-5.[4]Mediators Inflamm 2018;2018:1395823.Acknowledgements:This study was supported by European Union FEDER funds and “Fondo de Investigaciones Sanitarias” (grant PI18/00042) from ‘Instituto de Salud Carlos III’ (ISCIII, Health Ministry, Spain). DP-P is a recipient of a Río Hortega programme fellowship from the ISCIII, co-funded by the European Social Fund (ESF, `Investing in your future´) [grant number CM20/00006]; SR-M is supported by funds of the RETICS Program co-funded by the European Regional Development Fund (ERDF) [grant number RD16/0012/0009]; VP-C is supported by a pre-doctoral grant from IDIVAL [grant number PREVAL 18/01]; BA-M is a recipient of a `López Albo´ Post-Residency Programme funded by Servicio Cántabro de Salud; LL-G is supported by funds of IDIVAL [grant number INNVAL20/06]; RL-M is a recipient of a Miguel Servet type I programme fellowship from the ISCIII, co-funded by the European Social Fund (ESF, `Investing in your future´) [grant number CP16/00033].Disclosure of Interests:Diana Prieto-Peña: None declared, Fernanda Genre: None declared, Sara Remuzgo Martinez: None declared, Verónica Pulito-Cueto: None declared, Belén Atienza-Mateo: None declared, Belén Sevilla: None declared, Javier Llorca: None declared, Norberto Ortego: None declared, Leticia Lera-Gómez: None declared, Maite Leonardo: None declared, Ana Peñalba: None declared, Luis Martín-Penagos: None declared, Jose Alberto Miranda-Filloy: None declared, J. Narváez: None declared, LUIS CAMINAL MONTERO: None declared, PAZ COLLADO: None declared, Antonio Fernandez-Nebro: None declared, Gisela Díaz-Cordoves: None declared, Secundino Cigarrán: None declared, Jesús Calviño: None declared, Carmen Cobelo: None declared, Javier Sanchez Perez: None declared, Diego de Argila: None declared, Esteban Rubio-Romero: None declared, MANUEL LEON LUQUE: None declared, Juan María Blanco-Madrigal: None declared, E. Galindez: None declared, Javier Martin Ibanez: None declared, Santos Castañeda: None declared, Ricardo Blanco Speakers bureau: Abbvie, Pfizer, Roche, Bristol-Myers, Janssen and MSD, Consultant of: Abbvie, Pfizer, Roche, Bristol-Myers, Janssen and MSD, Grant/research support from: Abbvie, MSD and Roche, Miguel A González-Gay Speakers bureau: Pfizer, Abbvie, MSD, Grant/research support from: Pfizer, Abbvie, MSD, Raquel López-Mejías: None declared
43
Prieto-Peña, D., S. Remuzgo Martinez, F. Genre, et al. "POS0113 BAFF-APRIL-BAFFR PATHWAY ON THE PATHOGENESIS OF IMMUNOGLOBULIN-A VASCULITIS." Annals of the Rheumatic Diseases 80, Suppl 1 (2021): 267.2–268. http://dx.doi.org/10.1136/annrheumdis-2021-eular.707.
Full textAbstract:
Background:BAFF, APRIL and BAFFR are genes that encode cytokines with a key role in the development and survival of B-lymphocytes [1-4]: The B cell-activating factor (BAFF, also known as BLyS), a proliferation-inducing ligand (APRIL) and BAFF receptor (BAFF-R), respectively. Previous genetic studies have revealed that the BAFF-APRIL-BAFFR pathway is implicated in the genetic predisposition to several immune-mediated diseases [5].Objectives:To determine whether the BAFF-APRIL-BAFFR pathway represents a novel genetic risk factor for the pathogenesis of Immunoglobulin-A vasculitis (IgAV), an inflammatory disease in which IgA deposits and B-lymphocytes are crucial [6, 7].Methods:A functional BAFF polymorphism (rs374039502) and two tag variants within APRIL (rs11552708 and rs6608) and BAFFR (rs7290134 and rs77874543) were genotyped in 386 Caucasian IgAV patients (the largest series of Caucasian patients with IgAV ever assessed for genetic studies) and 806 sex and ethnically matched healthy controls by TaqMan assays.Results:No statistically significant differences in the genotype and allele frequencies between patients with IgAV and healthy controls were observed when each genetic variant of BAFF APRIL and BAFFR was analyzed independently (Table 1). Likewise, no statistically significant differences in genotype and allele frequencies of BAFF APRIL or BAFFR were found when patients with IgAV were stratified according to the age at disease onset or to the presence/absence of gastrointestinal or renal manifestations. Similar results were disclosed when haplotype frequencies of APRIL and BAFFR were compared between patients with IgAV and healthy controls as well as patients with IgAV stratified according to the age at disease onset or to the presence/absence of gastrointestinal or renal manifestations.Conclusion:Our results suggest that the BAFF-APRIL-BAFFR pathway does not contribute to the genetic network underlying IgAV.References:[1]J Exp Med 1999;190:1697-710; [2] Science 1999;285:260-3; [3] Nat Genet 2005;37:829-34; [4] Nat Immunol 2002;3:822-9; [5] N Engl J Med 2017;376:1615-26; [6] N Engl J Med 2013;368:2402-14; [7] Autoimmun Rev 2018;17:301-315.Table 1.Genotype and allele frequencies of BAFF, APRIL and BAFFR genes in patients with IgA vasculitis and healthy controls.PolymorphismLocus1/2Data set1/11/22/212rs374039502BAFFT/APatients91.9 (353)8.1 (31)095.9 (737)4.1 (31)Controls91.5 (733)8.1 (65)0.4 (3)95.6 (1531)4.4 (71)rs11552708APRILG/APatients78.1 (299)20.6 (79)1.3 (5)88.4 (677)11.6 (89)Controls77.9 (625)20.4 (1641.6 (13)88.1 (1414)11.9 (190)rs6608APRILC/TPatients71.9 (277)26.0 (100)2.1 (8)84.9 (654)15.1 (116)Controls70.0 (561)27.6 (221)2.5 (20)83.7 (1343)16.3 (261)rs7290134BAFFRA/GPatients58.0 (224)36.3 (140)5.7 (22)76.2 (588)23.8 (184)Controls57.2 (459)36.4 (292)6.5 (52)75.3 (1210)24.6 (396)rs77874543BAFFRG/CPatients82.7 (316)16.0 (61)1.3 (5)90.7 (693)9.3 (71)Controls83.0 (666)16.6 (133)0.4 (3)91.3 (1465)8.7 (139)Acknowledgements:This study was supported by European Union FEDER funds and “Fondo de Investigaciones Sanitarias” (grant PI18/00042) from ‘Instituto de Salud Carlos III’ (ISCIII, Health Ministry, Spain). DP-P is a recipient of a Río Hortega programme fellowship from the ISCIII, co-funded by the European Social Fund (ESF, `Investing in your future´) [grant number CM20/00006]; SR-M is supported by funds of the RETICS Program co-funded by the European Regional Development Fund (ERDF) [grant number RD16/0012/0009]; VP-C is supported by a pre-doctoral grant from IDIVAL [grant number PREVAL 18/01]; BA-M is a recipient of a `López Albo´ Post-Residency Programme funded by Servicio Cántabro de Salud; LL-G is supported by funds of IDIVAL [grant number INNVAL20/06]; RL-M is a recipient of a Miguel Servet type I programme fellowship from the ISCIII, co-funded by the European Social Fund (ESF, `Investing in your future´) [grant number CP16/00033].Disclosure of Interests:Diana Prieto-Peña Speakers bureau: Abbvie, Pfizer, Roche, Bristol-Myers, Janssen and MSD, Consultant of: Abbvie, Pfizer, Roche, Bristol-Myers, Janssen and MSD, Grant/research support from: Abbvie, MSD and Roche, Sara Remuzgo Martinez: None declared, Fernanda Genre: None declared, Verónica Pulito-Cueto: None declared, Belén Atienza-Mateo: None declared, Belén Sevilla: None declared, Javier Llorca: None declared, Norberto Ortego: None declared, Leticia Lera-Gómez: None declared, Maite Leonardo: None declared, Ana Peñalba: None declared, J. Narváez: None declared, Luis Martín-Penagos: None declared, Jose Alberto Miranda-Filloy: None declared, LUIS CAMINAL MONTERO: None declared, PAZ COLLADO: None declared, Javier Sanchez Perez: None declared, Diego de Argila: None declared, Esteban Rubio-Romero: None declared, MANUEL LEON LUQUE: None declared, Juan María Blanco-Madrigal: None declared, E. Galindez: None declared, Javier Martin Ibanez: None declared, Santos Castañeda: None declared, Ricardo Blanco Speakers bureau: Abbvie, Pfizer, Roche, Bristol-Myers, Janssen and MSD, Consultant of: Abbvie, Pfizer, Roche, Bristol-Myers, Janssen and MSD, Grant/research support from: Abbvie, MSD and Roche, Miguel A González-Gay Speakers bureau: Pfizer, Abbvie, MSD, Grant/research support from: Pfizer, Abbvie, MSD, Raquel López-Mejías: None declared
44
Marchant Rivera, Alicia. "Fuentes documentales para un esbozo del arte sartorial: sastres de príncipes, reyes y nobles en la Corona de Castilla en los inicios de la Modernidad." Vínculos de Historia. Revista del Departamento de Historia de la Universidad de Castilla-La Mancha, no. 8 (June 20, 2019): 296. http://dx.doi.org/10.18239/vdh_2019.08.15.
Full textAbstract:
RESUMENCon el presente trabajo se pretende, sobre el soporte bibliográfico que registra la trayectoria del gremio sartorial, aportar un enfoque inédito proporcionado por las fuentes archivísticas y documentales para la época: la identificación, relación y análisis de la función ejercida por los sastres de los reyes y de aquellos vinculados al estamento nobiliario en la horquilla cronológica seleccionada, comprendida entre los años 1450 y 1615, fecha del primer y último documento trabajados en este sentido. Esta línea de investigación nos permitirá descubrir desde individuos con deseos de medrar en la escala social, como los sastres andantes y estantes en corte, hasta un subgrupo más consolidado marcado por la continua insatisfacción de las deudas por parte de la nobleza. Secciones archivísticas como el Registro General del Sello, Cámara de Castilla, Registro de Ejecutorias o Consejo de Estado, pertenecientes a variados archivos estatales españoles, nos servirán para proporcionar una nutrida nómina, en relación diacrónica, de los sastres vinculados a la Corona castellana en este periodo. Por otro lado, se destacará el proteccionismo regio hacia la figura de este artesano cercano a las élites de poder, ejemplificándolo en figuras concretas. Finalmente se apuntarán las posibilidades de la documentación analizada para conocer en profundidad, y de la mano de fuentes históricas primarias, aspectos de la historia del vestido regio y del de los empleados de la corte.PALABRAS CLAVE: sastres, reyes, nobles, Corona de Castilla, 1450-1615ABSTRACTThe aim of the present work is, on the basis of the literature that records the trajectory of the sartorial profession, to offer a new approach provided by the archival and documentary sources of the time: the identification, relation and analysis of the function exerted by tailors to kings and to those linked to the nobility. This line of research will allow us to discover people ranging from individuals seeking to climb the social ladder, such as tailors living at the court, to a more consolidated subgroup marked by the continued non-payment of debts by the nobility. Archival sections such as the General Registry of the Seal, Chamber of Castile, Registry of Executives or Council of State, belonging to various Spanish state archives, will provide us with a long list, in diachronic terms, of the tailors linked to the Castilian Crown between 1450 and 1615, the dates of the first and last documents used for this purpose. Furthermore, I shall highlight royal protectionism vis-à-vis the figure of this craftsman close to the elites, offering specific examples. Finally, I shall refer to the potential of the documentation analysed to explore in depth, and via primary historical sources, aspects of the history of royal attire and that of court employees.KEY WORDS: tailors, kings, nobles, Crown of Castile, 1450-1615 BIBLIOGRAFÍAAlcega, J. de, Tratado de Geometría, Práctica y Traza, el cual trata de lo tocante al oficio de sastre…, Valladolid, Maxtor, 2009.Alvar Ezquerra, A., El nacimiento de una capital europea: Madrid entre 1561 y 1609, Madrid, Turner, 1989.Baleztena Abarrategui, J., “Ordenanzas contra los sastres que tuvieren paños faltosos (1533)”, Cuadernos de etnología y etnografía de navarra, 74 (1999), pp. 563-570.Bello León, J. M., y Hernández Pérez, M. B., “Una embajada inglesa a la corte de los Reyes Católicos y su descripción en el ‘Diario’ de Roger Machado”, En la España medieval, 26 (2003), pp. 167-202.Bouza Brey, F., “Historia de la cofradía gremial de sastres de Santiago de Compostela”, Revista Compostellanum, 7 (1962), pp. 569-620.Carretero Rubio, V., La artesanía textil y del cuero en Málaga (1487-1525), Málaga, Cedma, 1996.Comisión Internacional de Diplomática, Folia Caesaraugustana I (normas de transcripción y edición de documentos), Zaragoza, CSIC, Institución Fernando el Católico, 1984.Domínguez Ortiz, A., “Madrid de villa a corte”, en Historia y documentos notariales, Madrid, 16-2 (1992), pp. 263-279.Falcón Pérez, M. I., “Sobre la industria del vestido en Zaragoza en el siglo XV: las ordenanzas de la cofradía de sastres, calceteros y juboneros”, Aragón en la Edad Media, 12 (1995), pp. 241-266.Fernández García, J., “La consideración social de los sastres en la tradición asturiana: (poesía popular y paremiología)”, en Polledo Arias, A. C. (coord.), Fiestas Balesquida, Oviedo, 2012, pp. 89-103.Francisco Olmos, J. M. de, “La evolución de los cambios monetarios en el reinado de Isabel la Católica según las cuentas del tesorero Gonzalo de Baeza”, En la España medieval, 21 (1998), pp. 115-142.Gestoso Pérez, J. y Fernández Gómez, M., Noticia histórico-descriptiva del antiguo pendón de la ciudad de Sevilla y de la bandera de la Hermandad de los sastres, Sevilla, Área de Cultura, 1999.Gómez de Valenzuela, M., “La regla de la cofradía jaquesa de sastres, bajo la advocación de San Lorenzo (1602)”, Argensola: Revista de CC. Sociales del Instituto de Estudios Altoaragoneses, 113 (2003), pp. 315-328.González Arce, J. D., “De la corporación al gremio. La cofradía de sastres, jubeteros y tundidores burgaleses en 1485”, Studia historica. Historia medieval, 25 (2007), pp. 191-219.González Arce, J. D., La casa y corte del príncipe don Juan (1478-1497): economía y etiqueta en el palacio del hijo de los Reyes Católicos, Sevilla, Sociedad Española de Estudios Medievales, 2016.González Marrero, M. del C., “Un vestido para cada ocasión: la indumentaria de la realeza bajomedieval como instrumento para la afirmación, la imitación y el boato. El ejemplo de Isabel I de Castilla”, Cuadernos del CEMyR, 22 (2015), pp. 155-194.Haldón Reina, J. F., “Aproximación histórico-artística a la antigua Hermandad de Nuestra Señora de los reyes del gremio de sastres”, en Roda Peña, J. (coord.), II Semana de estudios Medievales, Nájera, 2009, pp.155-190.Juárez-Almendros, E., “Don Quijote y la moda: El legado de Carmen Bernis”, Cervantes: Bulletin of the Cervantes Society of America, 24.1 (2004), pp. 137-142.López García, J. M., El impacto de la corte en Castilla: Madrid y su territorio en la época moderna, Madrid, siglo XXI de España, 1998.Marchant Rivera, A., “Los sastres en los Procesos de fe del tribunal de distrito de la Inquisición de Toledo (1483-1597)”, Documenta & Instrumenta, 12 (2014), pp. 95-116.Martínez Carreño, A., “Sastres y modistas: notas alrededor de la historia del traje en Colombia”, Boletín Cultural y Bibliográfico, vol. 28, n. 28 (1991), pp. 61-76.Mediero Velasco, M. I., “El impacto de la corte sobre la villa de Madrid”, Pasea por Madrid: historia, turismo cultural y tiempo libre, 7 (2015), pp. 39-57.Monner Sans, R., De sastres: entretenimiento paremiológica, Talleres de la Casa Jacobo Peuser, 1909.Nieto Sánchez, J. A., “La conflictividad laboral en Madrid durante el siglo XVII: el gremio de sastres”, en Actas del I Congreso de jóvenes Geógrafos e Historiadores, 1995, pp. 283-289.Nieto Sánchez, J. A., Artesanos y mercaderes: una historia social y económica de Madrid (1450-1850), Madrid, Fundamentos, 2006.Nombela Rico, J. M., Auge y decadencia en la España de los Austrias: la manufactura textil de Toledo en el siglo XVI, Toledo, Ayuntamiento, 2003.Puerta Escribano, R. de la, “Los avatares del asociacionismo de los artífices del vestir en la Valencia Moderna”, en Prats, L. (coord.), Estudios en homenaje a la Profesora Teresa Puente, vol. 2, Valencia, 1996, pp. 481-495.Puerta Escribano, R. de la, Historia del gremio de sastres y modistas en Valencia: del siglo XIII al siglo XX, Valencia, Ayuntamiento, 1997.Puñal Fernández, T., Los artesanos de Madrid en la Edad Media (1200-1474), Madrid, UNED, 2000.Reguera Ramírez, R., “Costureras versus sastres. También una cuestión de género”, El Pajar: Cuaderno de etnografía canaria, 25 (2008), pp. 110-116.Rodríguez Plaza, M. Á., “Ordenanzas del gremio de sastres de Plasencia. Año 1795”, Revista de estudios extremeños, vol. 71, n. 2 (2015), pp. 1115-1136.Salazar y Castro, L., Pruebas de la historia de la casa de Lara sacadas de los instrumentos por…, Madrid, Imprenta Real, 1694, p. 102.Sanchís Llorens, R., “El offici de sastres y calcetters de Alcoy”, en Primer Congreso de Historia del País Valenciano: celebrado en Valencia del 14 al 18 de abril de 1971, vol. 3, Valencia, 1976, pp. 201-208.Vaamonde Lores, C., “La cofradía de los sastres de Betanzos”, Boletín de la Real Academia Galega, 46 (1911), pp. 244-251.Zofío Llorente, J. C., “Reproducción social y artesanos. Sastres, curtidores y artesanos de la madera madrileños en el siglo XVII”, Hispania: Revista española de Historia, 71/237 (2011), pp. 87-120.Zofío Llorente, J. C., Gremios y artesanos en Madrid, 1550-1650: la sociedad de trabajo en una ciudad cortesana preindustrial, Madrid, CSIC, 2005.
45
Iñiguez Jiménez, Samuel Olegario, Isaac Josué Iñiguez Jiménez, Stephanie Marie Cruz Pierard, and Alicia Carolina Iñiguez Jiménez. "Relación entre uso problemático de internet y calidad de sueño durante la pandemia de COVID-19." Universidad Ciencia y Tecnología 25, no. 109 (2021): 116–23. http://dx.doi.org/10.47460/uct.v25i109.457.
Full textAbstract:
Se analizó la relación entre el uso problemático de internet y la calidad de sueño. La metodología fue no experimental, transversal y correlacional. La muestra fue no probabilística por conveniencia. Participaron 118 estudiantes de pregrado y postgrado de universidades e institutos superiores de la ciudad de Quito en Ecuador. Los instrumentos fueron el Cuestionario de Experiencias Relacionadas con Internet (CERI) y el Cuestionario de Pittsburg de Calidad de Sueño (PSQI). Se evaluó la asociación entre las variables mediante el coeficiente de correlación de Pearson y un valor p < 0,05 durante la emergencia sanitaria por COVID-19. Los resultados muestran que los participantes en 51 % tienen problemas ocasionales con el uso de internet y el 47 % tienen problemas de sueño que además merecen atención y tratamiento médico. La asociación entre la variable independiente y la variable dependiente fue r = 0,195 y p = 0,034. En conclusión, existe una relación significativa moderada entre el uso problemático de internet y la calidad de sueño.
 Palabras Clave: Calidad de sueño, estudiantes universitarios, salud mental, uso de internet.
 [1]D. J. Kuss y O. López-Fernández, “Internet addiction and problematic Internet use: A systematic review of clinical research,” World journal of psychiatry vol. 6, n° 1, pp. 143-76, Marzo 2016.
 [2]M. Vázquez-Chacón, S. Cabrejos-Llontop, Y. Yrigoin-Pérez, R. Robles-Alfaro y C. Toro-Huamanchumo, “Adicción a internet y calidad de sueño en estudiantes de medicina de una Universidad peruana, 2016,” Revista Habanera de Ciencias Médicas, vol. 18, n° 5, pp. 817-830, Octubre 2019.
 [3]P. Carrillo-Mora, K. Barajas-Martínez, I. Sánchez-Vázquez y M. Rangel-Caballero, “Trastornos del sueño: ¿qué son y cuáles son sus consecuencias?,” Revista de la Facultad de Medicina de la UNAM, vol. 61, n° 1, pp. 6-20, Enero-febrero 2018.
 [4]S. J. Kim, J. W. Kim, Y. S. Cho, K. J. Chung, H. Yoon y K. H. Kim, “Influence of Circadian Disruption Associated With Artificial Light at Night on Micturition Patterns in Shift Workers,” International neurourology journal, vol. 23, n° 4, pp. 258-264, Diciembre 2019.
 [5]J. Arendt y B. Middleton, “Human seasonal and circadian studies in Antarctica (Halley, 75°S),” General and Comparative Endocrinology, vol. 258, n° 1, pp. 250-258, Marzo 2018.
 [6]P. Botero, P. Camargo, Y. Riaño y N. Velásquez, “Calidad del sueño en adultos según el grado de exposición a campos electromagnéticos en Bogotá y Duitama en 2017,” Tesis de pregrado, Universidad de Ciencias Aplicadas y Ambientales, Bogotá, COL., 2017.
 [7]H. Y. Wong, H. Y. Mo, M. N. Potenza, M. Chan, W. M. Lau, T. K. Chui, A. H. Pakpour y C. Y. Lin, “Relationships between Severity of Internet Gaming Disorder, Severity of Problematic Social Media Use, Sleep Quality and Psychological Distress,” International journal of environmental research and public health, vol. 17, n° 6, 1879, Marzo 2020.
 [8]V. Parra, J. Vargas, B. Zamorano, F. Peña, Y. Velázquez, L. Ruiz y O. Monreal, “Adicción y factores determinantes en el uso problemático del Internet, en una muestra de jóvenes universitarios,” Edutec-e, n° 56, p. a337, Junio 2016.
 [9]M. Laguna, “Estudio sobre el uso de internet y sus aplicaciones en el alumnado de último año de carrera de la Universidad de Alicante,” Tesis Doctoral, Universidad de Alicante, Alicante, ESP., 2013.
 [10]A. Rial, P. Gómez, M. Isorna, M. Araujo y J. Varela, “EUPI-a: Escala de Uso Problemático de Internet en adolescentes. Desarrollo y validación psicométrica,” Adicciones, vol. 27, n° 1, pp. 47-63, 2015.
 [11]T. Fernández-Villa, J. Alguacil, A. Almaraz, J. Cancela, M. Delgado-Rodríguez, M. García-Martín, E. Jiménez-Mejías, J. Llorca, A. Molina, R. Ortíz, L. Félix y V. Martín, “Uso problemático de internet en estudiantes universitarios: factores asociados y diferencias de género,” Adicciones, vol. 27, n° 4, pp. 265-275, 2015.
 [12]S. Cañón, J. Castaño, D. Hoyos, J. Jaramillo, D. Leal, R. Rincón, E. Sánchez y L. Urueña, “Uso problemático de internet en estudiantes universitarios: factores asociados y diferencias de género,” Adicciones, vol. 27, n° 4, pp. 265-275, Julio-diciembre 2016.
 [13]Z. Granados-Carrasco, A. Bartra-Aguinaga, D. Bendezú-Barnuevo, J. Huamanchumo-Merino, E. Hurtado-Noblecilla, J. Jiménez-Flores, F. León-Jiménez y D. Chang-Dávila, “Calidad del sueño en una facultad de medicina de Lambayeque,” Anales de la Facultad de Medicina, vol. 74, n°4, pp. 311-314, Octubre-Diciembre 2013.
 [14]Q. Wang, K. Mati y Y. Cai, “The link between problematic internet use, problematic gaming, and psychological distress: does sleep quality matter?,” BMC psychiatry, vol. 21, n° 1, 103, Febrero 2021.
 [15]M. Bautista y I. Taipe, “Calidad de sueño y factores asociados en internos rotativos de la carrera de Medicina de la Universidad de Cuenca 2019,” Tesis de pregrado Médico Cirujano, Universidad de Cuenca, Cuenca, ECU., 2019.
 [16]El Universo. (2020, Junio 26). El tráfico de internet en los hogares creció hasta 63 % en medio de la pandemia del COVID-19. Diario El Universo [Internet]. Disponible en: https://www.eluniverso.com/noticias/2020/06/23/nota/7881924/internet-fijo-servicio-operadoras-demanda-cuarentena-covid-19.
 [17]B. Fernandes, U. Nanda, R. Tan-Mansukhani, A. Vallejo y C. Essau, “The impact of COVID-19 lockdown on internet use and escapism in adolescents,” Revista de Psicología Clínica con Niños y Adolescentes, vol. 7, n° 3, pp. 59-65, Septiembre 2020.
 [18]J. A. Casas, R. Ruiz-Olivares y R. Ortega-Ruiz, “Validation of the Internet and Social Networking Experiences Questionnaire in Spanish adolescents,” International Journal of Clinical and Health Psychology, vol. 13, n° 1, pp. 40-48, Enero 2013.
 [19]Y. Tan, Y. Chen, Y. Lu y L. Li, “Exploring Associations between Problematic Internet Use, Depressive Symptoms and Sleep Disturbance among Southern Chinese Adolescents,”International journal of environmental research and public health, vol. 13, n° 3, 313, Marzo 2016.
 [20]A. Barquero y F. Calderón, “Influencia de las nuevas tecnologías en el desarrollo adolescente y posibles desajustes,” Revista Cúpula, vol. 30, n° 2, pp. 11-25, 2016.
 [21]J. P. C. Chang y C. C. Hung. Uso problemático de internet. Libro electrónico de IACAPAP de Salud Mental en Niños y Adolescentes. Geneva: Asociación Internacional de Psiquiatría y Profesiones Aliadas de Niños y Adolescentes. [Internet]. 2016. Disponible en: https://iacapap.org/content/uploads/H.6-Uso-problem%C3%A1tico-de-Internet-SPANISH-2017.pdf
 [22]S. García y G. Zurita, “Estudio estadístico de internet y su incidencia en la educación universitaria fiscal de la provincia del Guayas,” Tesis de pregrado Ingeniera en Estadística Informática, Escuela Superior Politécnica del Litoral (ESPOL), Guayaquil, ECU., 2017.
 [23]J. Redondo, K. Rangel, M. Luzardo y C. Inglés, “Experiencias relacionadas con el uso de internet y celular en una muestra de estudiantes universitarios colombianos,” Revista Virtual Universidad Católica del Norte, vol. 49, pp. 7-22, Septiembre-diciembre 2016.
 [24]S. Cruces, R. Guil, N. Sánchez y J. Pereira, “Consumo de nuevas tecnologías y factores de personalidad en estudiantes universitarios,” Commons, vol. 5, n° 2, pp. 203-228, Diciembre 2016.
 [25]X. Carbonell, A. Chamarro, M. Griffiths, U. Oberst, R. Cladellas y A. Talam, “Problematic Internet and cell phone use in Spanish teenagers and young students,” Anales de psicología, vol. 8, n° 3, pp. 789-796, Octubre 2012.
 [26]S. Iñiguez-Jiménez, S. Cruz-Pierard y S. Vaca-Córdova, “Uso problemático de tecnologías de la información y comunicación, consumo de sustancias y su impacto en la salud mental de estudiantes de bachillerato,” PAIDEIA XXI, vol. 10, n° 2, pp. 471-489, Julio-diciembre 2020.
 [27]M. Machado-Duque, J. Echeverri y J. Machado-Alba,"Somnolencia diurna excesiva, mala calidad del sueño y bajo rendimiento académico en estudiantes de Medicina,” Revista Colombiana de Psiquiatría, vol. 44, n° 3, pp. 137-142, Julio-septiembre 2015.
 [28]S. de la Portilla, C. Dussán, D. Montoya, J. Taborda y L. Nieto, “Calidad de sueño y somnolencia diurna excesiva en estudiantes universitarios de diferentes dominios,” Hacia Promoc. Salud, vol. 24, n° 1, pp. 84-96, Enero – junio 2019.
 [29]F. Wang y É. Bíró, “Determinants of sleep quality in college students: A literature review,” Explore, vol. 17, n° 2, pp. 170-177, Marzo-abril 2021.
 [30]M. Puerto, D. Rivero, L. Sansores, L. Gamboa y L. Sarabia, “Somnolencia, hábitos de sueño y uso de redes sociales en estudiantes universitarios,” Enseñanza e Investigación en Psicología, vol. 20, n° 2, pp. 189-195, Mayo-agosto 2015.
 [31]Ministerio de Sanidad. “COVID-19, consumo de sustancias psicoactivas y adicción”. Observatorio Español de las Drogas y las Adicciones, España. Informe Impacto COVID. [Internet]. Julio 2020. Disponible en: https://pnsd.sanidad.gob.es/noticiasEventos/actualidad/2020_Coronavirus/pdf/20200715_Informe_IMPACTO_COVID-19_OEDA_final.pdf
46
Moody, Douglas. "Interview with Guillermo Gómez-Peña." Encrucijada 2, no. 1 (2004). http://dx.doi.org/10.1349/ps1.1543-3315.a.272.
Full text
47
Selistre, Jacks Ricardo, and Rosa Maria Blanca. "O ESPAÇO TRANSFRONTEIRIÇO E TRANSIDENTITÁRIO NA OBRA DE GUILLERMO GÓMEZ-PEÑA." Paralelo 31 2, no. 7 (2017). http://dx.doi.org/10.15210/p31.v2i7.10595.
Full textAbstract:
O presente estudo busca através da obra do artista mexicano/chicano Guillermo Gómez-Peña, discutir as ideias acerca dos deslocamentos identitários e fronteiriços, de modo a compreendê-los e questioná-los como construções sociais, assim analisando de que maneira o artista em suas obras solapa as concepções hegemônicas do meio artístico, social e fronteiriço a fim de compreender como o sistema identitário e fronteiriço se constitui na contemporaneidade. TRANSBORDER AND TRANSIDENTITY SPACE IN THE WORK OF GUILLERMO GÓMEZ-PEÑA Abstract: This paper seeks to discuss, in the artwork by Mexican/Chicano artist Guillermo Gómez-Peña, ideas concerning identity and border displacements, in order to understand and question them as social constructions, thus analysing in which way his work undermines hegemonic conceptions of art, social and border milieus, and to understand how border and identity systems are being constituted at this time.
48
De Oliveira, Marilda Oliveira. "Território e deslocamento na obra de Guillermo Gómez-Peña." Visualidades 5, no. 1 (2012). http://dx.doi.org/10.5216/vis.v5i1.18036.
Full text
49
Torres, Sonia. "Dois Guillermos, várias fronteiras: performances de identidade transnacional em Guillermo Verdecchia e Guillermo Gómez-Peña." Gragoatá 9, no. 17 (2005). http://dx.doi.org/10.22409/gragoata.2004n17a33320.
Full textAbstract:
Através do diálogo (muitas vezes implícito) com textos críticos que problematizam construções identitárias latino-americanas e Latinas como sendo fluidas entre si, este ensaio analisa a representação de identidades americanas fronteiriças, ou em trânsito, por parte de dois intelectuais que optam por identificar-se tanto como latino-americanos exilados quanta Latinos: os autores e atores performáticos Guillermo Gómez-Peña, mexicano assumidamente "chicanizado"; e Guillermo Verdecchia, canadense de origem argentina. Buscarei argumentar, ao longo deste trabalho, que a categoria Latino serve aos propósitos políticos dos artistas, em cujas performances "identidade" e uma forma de identificação informada por um vasto repertório de americanidades múltiplas, e em constante negociação.
50
Gómez-Peña, Guillermo, and Marcela Levi. "Uma estética Chica-Rioca em desenvolvimento: uma conversa poética entre Guillermo Gómez-Peña e Marcela Levi." GIS - Gesto, Imagem e Som - Revista de Antropologia 1, no. 1 (2016). http://dx.doi.org/10.11606/issn.2525-3123.gis.2016.116375.
Full text